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ABSTRACT OF THE DISSERTATION 
 
An Assessment of Glioblastoma Metabolism Reveals Pathway-Specific Targets for Therapy 
 
by 
 
Jantzen Sperry 
Doctor of Philosophy in Molecular and Medical Pharmacology 
University of California, Los Angeles, 2019  
Professor Harley I. Kornblum, Chair 
 
Glioblastoma (GBM) remains the most common and lethal primary brain tumor in adults 
despite concerted efforts to establish more effective treatments. The oncogenic-associated 
alterations that make GBM cells metabolically distinct from surrounding tissue also represent 
prime targets for the development of novel therapies. Due to the interconnectivity of signaling 
networks and the overall heterogeneity of the disease, identifying key metabolic pathways that 
drive neoplastic pathogenesis is essential to establishing more effective therapeutic strategies. In 
this dissertation, we performed expression analysis and unbiased metabolomics to better 
characterize metabolic differences between a cohort of patient-derived isocitrate dehydrogenase 1 
(IDH1) mutant and wildtype gliomasphere cultures. This analysis revealed clear, cell type-specific 
differences in glucose metabolism, nucleotide synthesis utilization, and DNA repair capacity 
following radiation that could be exploited for therapy. Furthermore, we investigated the ability of 
GBM cells to oxidize fatty acids (FAO) and ketone bodies to support tumor growth, while also 
interrogating the effectiveness of the ketogenic diet (KD) as an adjuvant therapy for GBM. We 
 iii 
discovered extensive FAO utilization throughout the GBM metabolome, identified CPT1A as a 
potential therapeutic target, and determined that the KD can have adverse effects on tumor growth. 
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Chapter 1 
 
Introduction 
 
Hallmarks of Cancer 
Oncogenesis is the process through which normal cells of the body transform into cancer 
cells.  This multifactorial progression includes a series of genetic alterations, such as oncogene 
activation or tumor suppressor inactivation, followed by complex cellular changes that result in 
unrestricted cell growth. With more than 100 distinct types of cancer, a far greater number of 
associated cancer subtypes, and an estimated 1.7 million new cases of cancer diagnosed in 2018 
in the United States alone, cancer is at the forefront of health concerns facing modern society2. In 
an effort to elucidate the essential characteristics of cancer and to help “the complexities of the 
disease […] become understandable in terms of a small number of underlying principles,” 
Hanahan and Weinberg outlined six fundamental physiologic changes that regulate malignant 
progression3. These changes include self-sufficiency in growth signals, limitless replicative 
potential, evasion of programmed cell death, insensitivity to growth-inhibitory signals, sustained 
angiogenesis, and tissue invasion and metastasis. Over a decade later, these Hallmarks of Cancer 
were amended to include two additional emerging hallmarks: reprogramming of energy 
metabolism and evading immune destruction4. Understanding the mechanisms through which 
cancer cells reprogram their metabolism, a process referred to as metabolic transformation and the 
primary focus of the work presented here, represents a critical step to developing and improving 
precision cancer therapies. 
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Glioma 
 One particular type of cancer that epitomizes the hallmarks set forth by Hanahan and 
Weinberg is glioma. Glioma comprises a broad category of brain tumors that develop from the 
supportive cells of the central nervous system (CNS). Gliomas make up nearly 30% of all primary 
CNS tumors and approximately 80% of malignant brain tumors5, 6. Gliomas are classified by 
regional location of the tumor, histologic characterization according to the cell type with which 
they share defined characteristics, and by pathologic criteria defined by the World Health 
Organization (WHO)7, 8. Low grade gliomas (grades 1 and 2) are well-differentiated, slow-
growing or benign tumors that are associated with better prognoses. High grade gliomas (grades 3 
and 4) are anaplastic, malignant tumors characterized histologically by increased cellularity, 
necrosis, and vascular proliferation9, 10. Glioblastoma (GBM), a grade IV astrocytoma, comprises 
54% of all gliomas making it the most common, aggressive, and therapy-resistant form of 
malignant brain cancer in adults5.5/16/19 2:36:00 PM Despite aggressive treatment which includes 
surgical resection followed by combined radiation and chemotherapy with temozolomide (TMZ), 
GBM remains incurable. This standard of care therapy only marginally extends life expectancy, 
leaving those diagnosed with the bleak prognosis of a 15 month median survival11. Thus, new 
treatment strategies for GBM are desperately needed.  
 
Glioblastoma: A Metabolic Disease 
 Like many other aggressive and therapy resistant cancers, GBM can be characterized as a 
formidable and multifaceted tumor system that rivals the complexity of organs8, 12. A fundamental 
contributor to this complexity is GBM’s unique metabolism that can be attributed to the numerous 
oncogenic signaling pathways activated during gliomagenesis. By definition, oncogenes and tumor 
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suppressors regulate tumor growth. The majority of these essential regulators also impact the 
expression and activity of metabolic enzymes. Likewise, there are examples of mutations to 
metabolic genes that also drive tumorigenicity. Cancer-associated alterations to these genes result 
in metabolic transformation that promotes the growth of actively dividing cells while 
simultaneously inhibiting signals responsible for growth suppression. GBM, therefore, can be 
characterized as a highly intricate and adaptable metabolic disease resulting from a series of 
interconnected and often redundant signaling pathways that drive neoplastic pathogenesis. 
 
PI3Kinase/Akt Signaling Network 
The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway is one of the major 
signaling networks associated with GBM and is activated in over 90% of all GBMs13. Activation 
of this pathway and its downstream target molecules functions as a central regulator of many 
cellular processes including, but not limited to, cell cycle progression, apoptosis, and metabolism13, 
14. PI3K is recruited to the cell membrane and activated through phosphorylation by receptor 
tyrosine kinases (RTKs) such as epidermal growth factor receptor (EGFR), the first protein linked 
to oncogenesis in GBM15. EGFR is amplified in ~40% of all GBMs with about half of those tumors 
expressing the constitutively active EGFRviii form16. It is estimated that over 60% of GBM 
patients have some form of genomic alteration to the EGFR/PI3K pathway17, 18. Another prominent 
regulator of this pathway, the tumor suppressor  phosphatase and tensin homolog (PTEN), is 
significantly altered in 30-40% of GBMs19. Similar to EGFR, loss of PTEN function by either 
deletion or mutation results in hyperactivation of PI3K signaling pathway. 
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The Warburg Effect 
Elevated PI3K/Akt signaling results in a number of metabolic changes that are fundamental 
to tumor physiology. Most prominently, this signaling cascade serves as a key driver behind the 
most documented metabolic phenotype in GBM, the Warburg effect20, 21, 22. The Warburg effect is 
the observation that cancer cells predominantly meet bioenergetic demands by utilizing a high rate 
of aerobic glycolysis followed by lactic acid fermentation in the cytosol. This is in contrast to the 
comparatively low rate of glycolysis occurring in most healthy differentiated tissues, which depend 
instead on oxidation of pyruvate in the mitochondria. Hyperactivation of PI3K/Akt and other 
similar cancer-associated signaling networks cause GBM cells to shift their metabolism away from 
oxidative phosphorylation (OxPhos), making them highly reliant on elevated glucose flux 
instead23. Phosphorylation of Akt results in increased expression and activation of GLUT1, a 
protein localized to the plasma membrane that mediates transport of glucose into the cell24. 
Pathway activation also promotes the binding of hexokinase 2 (HK2) to voltage-dependent ion 
channels, once again stimulating increased glucose uptake and aerobic glycolysis25. Aerobic 
glycolysis is further promoted through increased phosphofructokinase 1 (PKFP1) activity and 
stability as a direct result of Akt activation resulting from PTEN loss and EGFR-dependent PI3K 
induction26.  
 The metabolic adaptation of GBM cells to utilize the Warburg effect extends far beyond 
simply the production of ATP for bioenergetic demands. In fact, aerobic glycolysis represents a 
less efficient means of generating ATP than mitochondrial respiration on a per mole of glucose 
basis27. Although, because glycolysis rates are significantly elevated in cancer, the total amount of 
ATP generated over any given period of time is comparable to that of OxPhos22, 28. In addition to 
ATP production, the Warburg effect may play a number of other important roles. Glucose acts as 
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a carbon source for the de novo production of lipids, nucleotides, and proteins that are essential for 
supporting sustained proliferation29, 30, 31. Increased glucose uptake also elicits excess production 
of reducing equivalents such as NADPH that are required for de novo biosynthetic processes32. 
Finally, it has been proposed that the Warburg effect may promote enhanced invasiveness33, 
immune evasion34, and angiogenesis35 through the production and release of lactate into the tumor 
microenvironment, and may also play a key role in the regulation of reactive oxygen species (ROS) 
levels28, 36. 
 Despite knowledge of this metabolic phenomenon for nearly a century, little progress has 
been made in establishing an effective therapeutic strategy targeting glucose metabolism in GBM. 
Several approaches for targeting EGFR have yielded underwhelming results in clinical trials. 
Receptor tyrosine kinase (RTK) inhibitors for EGFR such as erlotinib, gefitinib, lapatinib, afatinib 
have all been investigated, but none of these have demonstrated efficacy either alone or in 
combination with other drugs or small molecule inhibitors37, 38, 39, 40. Most of these studies site poor 
brain penetrance, lack of specificity, and activation of redundant RTK pathways as reasons for the 
ineffectiveness. Similar trials with EGFR-specific monoclonal antibodies such as Cetuximab and 
Nimotuzumab have also failed to result in large-scale benefits, although Nimotuzumab has shown 
more promising results in patients with GBMs that are O-6-methylguanine-DNA 
methyltransferase (MGMT) non-methylated41. Early clinical trials investigating first generation 
pan-PI3K inhibitors (wortmannin and LY294002) were also ineffective due to poor solubility, off-
target effects, and toxicity42. However, newer generation inhibitors targeting the PI3K/Akt/mTOR 
signaling axis have shown increased specificity and efficacy and have thus entered into clinical 
trials for GBM43. Due to the adaptability of GBM metabolism and the overlapping signaling 
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pathways that regulate it, it has yet to be determined if glucose metabolism can be a beneficial 
target in GBM.   
 
Isocitrate Dehydrogenase 1 (IDH) 
In addition to oncogenic signaling pathways such as EGFR/PI3K/Akt that drive 
tumorigenesis by altering tumor metabolism, there are also examples of mutations to metabolic 
genes that cause tumorigenicity. The most prominent example of this in GBM are isocitrate 
dehydrogenases (IDH1/2). IDH1 is a homodimeric enzyme localized to the cytoplasm and 
peroxisomes of cells, whose wildtype function is to produce alpha-ketoglutarate through the 
oxidative decarboxylation of isocitrate as part of the TCA or citric acid cycle. A mutation in IDH1 
at the arginine 132 residue (R132H), however, causes a neomorphic gain of function that further 
converts alpha-ketoglutarate to the proposed oncometabolite 2-hydroxyglutarate (2-HG)44. This 
particular IDH1 mutation is present in nearly 80% of grade II-III gliomas45, 46, 47, but also occurs 
in a smaller subset of GBMs48, 49. With regard to clinical prognosis, IDH mutations serve as 
favorable prognostic biomarkers for both overall and progression-free survival50, 46. An analogous 
but mutually exclusive mutation at residue R172 in IDH2, a member of the IDH gene family 
localized to the mitochondria, is also found in glioma. This mutation similarly results in gain-of-
function production of 2-HG, although it is far less common than that of IDH150. Recently, several 
compelling studies indicate IDH mutations occur early in gliomagensis51, 50, 52. This fact, combined 
with the overall prevalence of these mutations throughout gliomas, would seem to suggest IDH 
mutations are key events in tumorigenesis while reinforcing the significance of metabolic 
transformation in this process. However, determining whether oncogenic transformation is a result 
 7 
of the IDH mutation itself, the resulting 2-HG production, or a combination of both has yet to be 
fully established. 
In addition to 2-HG production, IDH mutations are also often associated with genome-
wide DNA hypermethylation called Glioma CpG Island Methylation Phenotype (G-CIMP)53, a 
valuable determinant of tumor pathogenicity. G-CIMP can result in the reorganization of both the 
methylome and transcriptome of these mutant tumors, although the comprehensive effects of this 
process are still being investigated54. In addition to being a major enzyme in the citric acid cycle, 
IDH may also serve several other important functions. Wildtype activity of IDH, the production 
of alpha-ketoglutarate from isocitrate, also results in the generation of nicotinamide adenine 
dinucleotide phosphate (NADPH) from NADP+, a critical reducing agent shown to regulate 
certain aspects of macromolecular biosynthesis, glutathione (GSH) production, ROS generation, 
and DNA repair in glioma55, 56, 57. The manner in which the IDH1 mutation and 2-HG production 
alter these processes will be covered in a later chapter, however, two things have become 
increasingly apparent. The IDH1 mutation serves a role extending far beyond TCA-mediated 
metabolism, and studies involving IDH1 mutant tumors reinforce the idea that brain tumors are, 
in fact, metabolic diseases. 
 
Fatty acid Metabolism 
 The role of glucose metabolism in brain tumors has been extensively documented over the 
past two decades. Yet more recent evidence has made it abundantly clear that gliomas utilize other 
metabolic substrates to meet bioenergetic demands and produce the raw materials required to 
sustain uncontrolled proliferation. One particular type of substrate that has drawn interest of late 
are fatty acids (FAs). FAs are a diverse class of molecules performing an equally diverse set of 
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functions within the cell. Some of the roles of FAs include: serving as molecular building blocks 
for membrane biosynthesis, acting as storage reservoirs for energy production, and assisting in 
both inter- and intracellular signaling. Similar to what is observed with other metabolic substrates, 
however, the rates and manner of FA utilization can differ significantly when comparing healthy 
tissue to that of a rapidly dividing tumor. 
 
FA Synthesis: GBM vs. Healthy Brain 
 Fatty acid synthesis is the anabolic process of generating FAs from acetyl-CoA and 
NADPH. This process takes place in the cytoplasm where the majority of acetyl-CoA is derived 
from glucose via glycolytic flux through the TCA cycle. Glucose-derived acetyl-CoA cannot be 
exported directly to the cytoplasm for FA synthesis, however. It must first be condensed with 
oxaloacetate to produce citrate in the TCA cycle. Excess citrate in the TCA cycle is converted to 
acetyl-CoA by ATP citrate lyase (ACLY), an enzyme directly phosphorylated and activated by 
Akt32, followed by decarboxylation of acetyl-CoA into malonyl-CoA. Malonyl-CoA is an 
important molecule because it functions as both a substrate for FA synthesis and as an inhibitor of 
fatty acid oxidation, a process that will be covered shortly58. When glucose is prevalent in GBM, 
excess acetyl-CoA can be used to generate high levels of malonyl-CoA that drive fatty acid 
synthesis for use in membranes to support proliferation. When malonyl-CoA levels drop, FA 
synthesis slows, allowing GBM cells to compensate for decreased glucose availability by shifting 
toward FA catabolism in support of survival. This process, which is significantly amplified in 
GBM relative to surrounding brain tissue, bestows an adaptable advantage to changing nutrient 
levels in the tumor microenvironment59. In addition to acting as a metabolic switch, malonyl-CoA 
represents the molecular building block by which fatty acid synthase (FASN) generates palmitate, 
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the first fatty acid produced which also serves as the precursor for synthesis of longer chain fatty 
acid molecules60, 59. FASN is therefore a critical enzyme regulating de novo FA synthesis, and 
indeed, increased expression of this enzyme correlates with malignancy in glioma61.  
 As mentioned previously, GBMs are highly versatile malignancies that rival the 
complexity of organs12. Thus, cellular processes such as FA synthesis can only occur if they are 
supported by GBM’s innate metabolic machinery and are conducive to the tumor 
microenvironment. Due to the abnormal vascularization present in GBM, persistence of FA 
synthesis under conditions of metabolic stress is key to supporting the unmitigated proliferative 
potential of these tumors. Importantly, FA metabolism has been shown to persist under conditions 
of hypoxia and low nutrient availability62. Low oxygen levels result in hypoxia inducible factor 1 
(Hif1)-mediated activation of sterol regulatory element-binding protein (SREBP)-1, the major 
transcriptional regulator of fatty acid synthase (FASN)63. Hypoxia also induces storage of FAs in 
lipid-rich cellular organelles called lipid droplets. Upon reoxygenation, the sequestered fatty acids 
are then used for ATP production through β-oxidation64. Because of the elevated rate of FA 
synthesis in GBM, the ability to store intracellular FAs has the added benefit of circumventing 
lipotoxicity and endoplasmic reticulum (ER) stress65.  
 
FA Beta-Oxidation: GBM vs. Healthy Brain 
 In contrast to fatty acid synthesis, fatty acid oxidation (FAO) is the catabolic process 
through which long-chain FAs are broken down in the mitochondria to generate acetyl-CoA. This 
process was largely overlooked in GBM until recently, likely due to misconceptions that fatty acids 
are unable to cross the blood brain barrier (BBB) and that the extent to which FAO takes place in 
the brain is negligible. It has been demonstrated that non-esterified fatty acids such as palmitic 
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acid and arachidonic acid are able to cross the BBB by simple diffusion while other fatty acids 
enter through passive diffusion66, 67. It is true that very little FAO takes place in neurons. Several 
hypotheses for this have been proposed: 1) generating ATP through FAO demands more oxygen 
than glucose which risks hypoxia in neurons68, 69, 2) FAO generates superoxide to which neurons 
have poor antioxidative defenses70 and 3) the process of ATP generation from tissue-derived fatty 
acids is slower than that of blood glucose71. A more recent study estimates that FAO may actually 
account for 15-20% of total brain oxidative energy production, but that this process occurs 
primarily in glial cells rather than in neurons72. Unlike neurons and other healthy brain cells, 
however, GBMs thrive under hypoxic conditions. FAs are also easily stored within tumor cells for 
use during nutrient deprivation. And given the highly invasive nature of GBM, these FAs also 
represent an alternative energy source as tumor cells migrate away from vascular supplies of 
glucose.  
Several additional lines of evidence support the potential importance of FAO in GBM. A 
common characteristic of these tumors is the development of highly necrotic cores that contain 
substantial amounts of lipids and fatty acids73. This fact, along with the ability of fatty acids (FAs) 
to diffuse across the BBB, provide a readily available reservoir from which GBMs can access FA 
substrates required for beta-oxidation. In support of this, several studies using proton NMR (1H 
NMR) have shown that GBMs do in fact have a large and distinct lipid signature. Additional 
studies have revealed that long-chain fatty acids (LCFAs), those that participate in beta-oxidation, 
are among the most prevalent FAs found in GBM74, 75, 76. 
The rate-limiting enzyme of FAO is carnitine palmitoyltransferase 1 (CPT1) which is 
located on the outer mitochondrial membrane60. This enzyme catalyzes the transfer of the acyl 
group of long-chain fatty acyl-CoA to L-carnitine, thereby allowing FAs to enter the mitochondria 
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for subsequent oxidation. There are three isoforms of CPT1 expressed in humans (CPT1A, 
CPT1B, and CPT1C). It has only recently been shown that expression of all three isoforms is 
common in GBM, but a rare occurrence elsewhere in the body77. Because of the rate-limiting 
properties of CPT1, it has been proposed as a promising target for FAO inhibition. To target CPT1, 
etomoxir (ETOM) has been implemented for both in vitro and in vivo studies78. ETOM is a potent, 
irreversible, CPT1-specific inhibitor that acts on all three CPT1 isoforms. A preclinical study 
published in 2010 demonstrated that SF188 glioblastoma cells oxidize fatty acids, and that 
inhibition of FAO with ETOM had widespread effects which include: a reduction in cellular ATP 
levels, decreased viability, and decreases in both NADPH and glutathione (GSH) levels79. The 
latter correspond with observed increases in reactive oxygen species (ROS), suggesting FAO may 
also play an important role in antioxidative defense.  
It is of note that the high concentrations of ETOM (up to 1mM) typically used in such 
studies may have potential off-target effects. Recently, a group investigating the effects of ETOM 
in macrophages reported that excessive concentrations of ETOM (>3uM) caused depletion of free 
cellular coenzyme A (CoA) and inhibited adenine nucleotide translocase (ANT) and respiratory 
complex I80. ETOM has also been used in a clinical trial for congestive heart failure, but the study 
was discontinued due to the accumulation of certain enzymes associated with hepatotoxicity in 
~5% of patients81. These results highlight the importance of FAO in GBM metabolism and suggest 
that targeting this pathway with more potent and specific inhibitors may offer benefits 
therapeutically. 
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Ketone Metabolism:  
Another metabolic pathway that has drawn particular interest in cancer research lately is 
ketone metabolism. Because the majority of cancers rely extensively on glucose uptake and 
aerobic glycolysis, many researchers have theorized that the implementation of a ketogenic diet 
(KD) may serve as an effective adjuvant therapy82, 83, 84. The KD consists of a high fat, adequate 
protein, low carbohydrate diet. With traditional diets, carbohydrates are converted to glucose 
which then circulates throughout the body for fuel. The KD forces the body to primarily metabolize 
fats which are ultimately converted into ketone bodies (KBs) through a process called ketogenesis. 
KB production, of which ß-hydroxybutyrate (3-OHB) and acetoacetate are most prevalent, occurs 
primarily in the mitochondria of liver cells through the breakdown of fatty acids and ketogenic 
amino acids85. This process can be initiated by fasting, calorie restriction, strenuous exercise, or 
by dietary intervention such as with a KD. Circulating KBs are then taken up by tissues like the 
brain where they are converted back to acetyl-CoA for entry into the TCA cycle.  
The ability of the brain to compensate for decreased glucose availability by shifting its 
metabolism away from glycolysis and towards ketolysis has been extensively documented86, 87. In 
fact, the KD has been implemented clinically and has shown promise in treating certain cases of 
epilepsy and diabetes that are refractory to standard therapy88, 89, 90. Studies investigating the effects 
of prolonged fasting estimate ketone body oxidation can account for ~30-40% of the human body’s 
energy requirement and up to 60% of the brain91. This process has the added benefit of sparing 
what little glucose is available for cells that are unable to utilize KBs for energy production, such 
as erythrocytes and hepatocytes. The therapeutic premise of the KD for GBM, therefore, is reliant 
on the hypothesis that limiting glucose availability, combined with the inability of GBMs to fully 
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compensate with circulating KBs and FAs, will starve the tumor of necessary nutrients without 
harming healthy tissues. 
The extent to which gliomas metabolize ketone bodies remains unclear. Several studies 
have suggested that gliomas may be unable to oxidize KBs for energy due to insufficient 
expression of the mitochondrial enzymes required to do so, such as acetyl-CoA acetyltransferase 
(ACAT), 3-oxoacid CoA transferase (OXCT1), and 3-hydroxybutyrate dehydrogenase 1 and 2 
(BDH1 and 2)92, 83, 93. Contrarily, another report determined that both neuroblastoma and glioma 
cells express these three enzymes at comparable levels to the brain, while also providing evidence 
that KBs may be utilized more for lipid synthesis rather than as substrates for energy production94. 
Preclinical studies investigating the effectiveness of the KD in animal brain tumor models have 
yielded mixed results. A study investigating ketone metabolism in two separate rat glioma models 
concluded that the level of KB oxidation (3-OHB) taking place within the tumor was comparable 
to that of normal contralateral brain tissue95. This group also determined that expression of 
monocarboxylate transporter 1 (MCT1), one of the primary enzymes responsible for KB uptake, 
becomes upregulated within glioma tissue of tumor-bearing animals when placed on the KD. 
Another group using a U87 mouse xenograft model found that the KD (administered ad libitum) 
was not sufficient to decrease circulating blood glucose and had no inhibitory effects on tumor 
growth96. Only when a calorie-restricted KD was implemented were there observed increases in 
blood ketone levels and corresponding decreases in blood glucose and tumor size. This brings into 
question whether the KD, calorie-restriction, or a combination of the two offers the greatest 
therapeutic benefit, as previous work has also demonstrated the anti-tumor effects of calorie 
restriction irrespective of the KD97, 98, 99.  
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While some of the above-mentioned studies may seem to contradict one another, it is likely 
that much of the disparity regarding KB metabolism in glioma arises from the heterogeneity of the 
disease. An assessment of ketolytic enzyme expression from 22 malignant glioma biopsies 
reinforces this point93. Mitochondrial expression of OXCT1 and BDH1 was found to be low (<20% 
positive cells relative to normal brain tissue) in most, but not all, of the tumors analyzed (14 of 17 
GBMs, 1 of 5 anaplastic gliomas). However, most of the 22 tumors were also positive (>20%) for 
cytosolic BDH2 and mitochondrial ACAT1. Thus, it is reasonable to theorize that tumors with 
lower mitochondrial expression of these ketolytic enzymes may respond better to dietary 
intervention than those with greater expression.  A more in-depth examination of the expression 
profiles of these critical ketolytic enzymes may be key to reconciling the true role of ketone 
metabolism in glioma and in directing future clinical approaches testing the effectiveness of KD 
therapy.  
 
Pathway Interconnectivity and Redundancy 
 One of the largest hurdles to overcoming therapy-resistant cancers is the interconnectivity 
and redundancy of metabolic pathways and oncogenic signaling. The genetic and epigenetic 
alterations that occur in GBM drive metabolic reprogramming that favors the growth of rapidly 
dividing cells while simultaneously inhibiting signals previously programmed to keep cellular 
division in check. Oncogenic signaling pathways such as PI3K/Akt/mTOR that drive glycolysis 
and regulate several other anabolic and catabolic processes within the cell are frequently activated 
in GBM. However, due to redundancy, targeted therapies to inhibit this pathway have failed to 
elicit beneficial results. For example, this pathway can be stimulated by loss of PTEN or through 
activation of receptor tyrosine kinases (RTKs) such as EGFR, PDGFRa, and MET100, 101. Thus, 
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GBMs can circumvent direct inhibition of EGFR by signaling instead through other RTKs. Akt 
can also be activated independently of PI3K by a series of Ser/Thr/Tyr kinases such as Src, ACK1 
(activated Cdc42-associated kinase), and PTK6 (Protein Tyrosine Kinase 6)102. To add to the 
complexity, mTOR can similarly be activated in a PI3K-independent manner through Wnt, Notch, 
and PDK1 (pyruvate dehydrogenase kinase 1) signaling103, 104, thereby providing additional 
resistance mechanisms to overcome direct PI3K/Akt inhibition. The intricacy and redundancy of 
such signaling networks present a major challenge that researchers must overcome in order to 
develop more effective therapies for aggressive cancers such as GBM.  
Another factor adding to the complexity of GBM physiology is the reality that metabolic 
pathways and the oncogene-directed modifications to these pathways do not occur in isolation. 
Breaking down cellular metabolism into individual pathways, as has been done here, can be highly 
useful for identifying targetable vulnerabilities. However, this approach often falsely 
oversimplifies the overall process. Substrates frequently participate in both catabolic and anabolic 
reactions that regulate one another. For example, AKT signaling promotes the catabolism of 
glucose through glycolysis for the purposes of generating ATP and lactate105. However, glucose 
catabolism also generates acetyl-CoA for anabolic biosynthesis of fatty acids in an Akt-dependent 
manner32. FAs can then be used to generate phospholipids for membrane production or can 
undergo FA beta-oxidation (FAO) to regenerate depleted stores of acetyl-CoA and NADH59. It has 
been shown that the acetyl-CoA and NADH produced during FAO can actually inhibit pyruvate 
dehydrogenase (PDH), which results in increased conversion of pyruvate to lactate106, 107. This 
process, often referred to as the Randle effect, demonstrates that FAO can actually promote the 
Warburg effect and represents just one example of the cross-regulation between metabolic 
pathways. Interestingly, FAs have also been shown to participate in “futile cycles”, a process 
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during which cells run two opposing metabolic pathways in parallel59. Under certain conditions, 
cancer cells will simultaneously activate both FA synthesis and FA oxidation. This process acts as 
a safeguard for maintaining adequate production of both ATP and lipids for membrane synthesis, 
while also serving as a dynamic switch that is highly sensitive to changes in nutrient availability 
and enzymatic activity108. 
The fact that cancers commonly display altered metabolic phenotypes from that of healthy 
tissue has been known for the better part of a century, when in the 1920’s Otto Warburg first 
reported that cancer cells utilize abnormally high rates of aerobic glycolysis20. However, despite 
decades of research and countless findings regarding this phenomenon, certain cancers such as 
GBM have continued to evade our grasp and our therapies. While GBM cells do metabolize 
glucose, it has become increasingly apparent in recent years that GBM is a complex metabolic 
disease, with the Warburg effect representing only a small chapter of a much larger story. The 
metabolic adaptations associated with oncogenic transformation bestow upon GBMs the increased 
flexibility to utilize multiple substrates (carbohydrates, lipids, ketones, and proteins) as energetic 
currency and as molecular building blocks to support their aggressive expansion. Understanding 
the interconnectivity and redundancy of oncogenic signaling networks, metabolic pathways, and 
cellular bioenergetics presents an enormous challenge to researchers. Yet, rapid technological 
advances and the ability to develop novel, target-specific drugs make targeting GBM metabolism 
one of the more promising approaches to establishing more effective therapies. 
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Chapter 2 
 
Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH 
wildtype gliomaspheres uncovers cell type-specific vulnerabilities 
 
Abstract 
 There is considerable interest in defining the metabolic abnormalities of IDH mutant 
tumors to exploit for therapy. While most studies have attempted to discern function by using cell 
lines transduced with exogenous IDH mutant enzyme, in this study we perform unbiased 
metabolomics to discover metabolic differences between a cohort of patient-derived IDH1 mutant 
and IDH wildtype gliomaspheres. Using both our own microarray and the TCGA datasets, we 
performed KEGG analysis to define pathways differentially enriched in IDH1 mutant and IDH 
wildtype cells and tumors. Liquid chromatography coupled to mass spectrometry analysis with 
labeled glucose and deoxycytidine tracers was used to determine differences in overall cellular 
metabolism and nucleotide synthesis. Radiation-induced DNA damage and repair capacity was 
assessed using a comet assay. Differences between endogenous IDH1 mutant metabolism and that 
of IDH wildtype cells transduced with the IDH1 (R132H) mutation were also investigated. Our 
KEGG analysis revealed that IDH wildtype cells were enriched for pathways involved in de novo 
nucleotide synthesis, while IDH1 mutant cells were enriched for pathways involved in DNA repair. 
LC-MS analysis with fully-labeled 13C-glucose revealed distinct labeling patterns between IDH1 
mutant and wildtype cells. Additional LC-MS tracing experiments confirmed increased de novo 
nucleotide synthesis in IDH wildtype cells relative to IDH1 mutant cells. Endogenous IDH1 
mutant cultures incurred less DNA damage than IDH wildtype cultures and sustained better overall 
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growth following X-ray radiation. Overexpression of mutant IDH1 in a wildtype line did not 
reproduce the range of metabolic differences observed in lines expressing endogenous mutations; 
but resulted in depletion of glutamine and TCA cycle intermediates, an increase in DNA damage 
following radiation, and a rise in intracellular ROS. These results demonstrate that IDH1 mutant 
and IDH wildtype cells are easily distinguishable metabolically by analyzing expression profiles 
and glucose consumption. Our results also highlight important differences in nucleotide synthesis 
utilization and DNA repair capacity that could be exploited for therapy. Altogether, this study 
demonstrates that IDH1 mutant gliomas are a distinct subclass of glioma with a less malignant, 
but also therapy resistant, metabolic profile that will likely require distinct modes of therapy. 
 
Background 
  Alteration in cellular metabolism is a key pathway to the development of cancer. Most 
oncogenes and tumor suppressors influence cellular metabolism, and there are examples of 
mutations in metabolic genes that become tumorigenic109. Homologous mutations in the metabolic 
enzymes isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are found in acute myelogenous 
leukemia, colon cancer and glioma51. In glioma, these mutations generally co-occur with either 
1p/19q co-deletion or with mutations in TP53, the former with more oligodendrocytic 
characteristics and the latter with more astrocytic characteristics110. In contrast to metabolic 
mutations that involve a loss of function, IDH mutations were found to bestow a new enzymatic 
function of reducing alpha-ketoglutarate (a-KG) to 2-hydroxyglutarate (2-HG)44. In the presence 
of IDH mutations, the 2-HG molecule, normally found at low levels, can increase to millimolar 
amounts. Understandably, there has been considerable interest in what role this potential 
“oncometabolite” might have on cells. Given the structural similarity of the 2-HG molecule to a-
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KG it was suspected that 2-HG may be a competitive inhibitor that blocked access to a-KG 
dependent enzymes that regulate cell epigenetics111, 112. 
 There has been considerable interest in defining what effects IDH mutations have on 
glioma cell biology, and what the discovery of an IDH mutation can tell us about a specific glioma.  
These questions are important for two reasons.  The first reason comes from the rationale that if 
the IDH mutant enzyme changes the metabolic state of the cell, this may render the cell more or 
less vulnerable to certain types of therapy. For example, it has been reported that the IDH1 
mutation makes cells more vulnerable to radiation113 or NAD+ depletion114.  This issue has become 
even more clinically relevant with the discovery that the presence of IDH mutations can be 
diagnosed via imaging even prior to surgery115. The second reason comes from the observation 
that glioblastoma patients with IDH mutant tumors have prolonged survival compared to patients 
with IDH wildtype tumors and that there are now pharmacological inhibitors of the IDH mutant 
enzymes available that block 2-HG formation116.  If it is the case that the IDH mutation is actually 
a metabolic burden to the cell, then use of these inhibitors may actually aid the tumor cell and 
accelerate growth.  Studies using mutant IDH inhibitors in in vivo xenograft models have led to 
mixed results with one showing slowed growth117 and another showing accelerated growth114. 
 Attempts to focus on isolating metabolic differences between IDH mutant and IDH 
wildtype glioblastomas have historically suffered from an unproven assumption that the metabolic 
differences between IDH mutant and IDH wildtype tumors can be largely attributed to the presence 
or absence of the IDH mutation itself118, 119.  However, more recent evidence suggests that IDH 
mutation may be one of the initial mutations to occur in those gliomas120, 52. Large-scale 
bioinformatics analyses of mutational, expression and epigenetic datasets reveals that IDH mutant 
and IDH wildtype tumors are different on a very fundamental level121 and may have different cells 
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of origin, and different paths of tumorigenesis.  Unfortunately, attempts to study cells derived from 
endogenous IDH mutant tumors have been hampered by the difficulty involved in establishing and 
maintaining IDH mutant glioma cells in culture.   
 To address these issues, we have performed a metabolic analysis on a cohort of patient-
derived IDH1 mutant and IDH wildtype tumor cells to determine differences between these groups 
that may potentially be exploitable for therapy.  We demonstrate that when compared to IDH 
wildtype glioma cells and tumors, IDH1 mutant cells and tumors are enriched for gene sets 
associated with DNA repair, while wildtype cells have greater expression of gene sets associated 
with nucleotide biosynthesis. IDH1 mutant cells have metabolic profiles that are distinct from 
those of IDH wildtype cells and our findings indicate that at least some of these differences are not 
corrected by overexpression of mutant IDH1 in IDH wildtype cells.  Functional studies 
surprisingly demonstrate that IDH1 mutant cells are better able to recover from radiation treatment 
and less prone to the effects of inhibition of de novo nucleotide biosynthesis.  These findings 
indicate that IDH mutant and wildtype tumors may be responsive to different metabolically-
directed therapies and that the previously held views that IDH mutant tumors are highly 
radiosensitive may not be correct for all subsets of IDH mutant tumors and needs further 
exploration. 
 
Results 
 KEGG GSEA analysis- Expression data from fifty-nine gliomasphere lines (52 IDH WT 
GBM and 7 IDH1 mutant) was subjected to Gene Set Enrichment Analysis (GSEA) using KEGG 
gene modules122, 123. Microarray data (GSE98995) is from data described in Laks et al, 2016124. A 
similar comparative analysis was performed on IDH1 mutant and IDH WT tumor samples in the 
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TCGA dataset (183 IDH1WT, 19 IDH1mut).  Each KEGG module was assigned a normalized 
enrichment score (NES) for each dataset and then plotted (Figure 1).  We noted a positive 
correlation between the gliomasphere and TCGA datasets giving confidence that our in vitro cells 
are a good model for in vivo tumors. 
There were fewer modules enriched in the IDH1 mutant group in both the TCGA (37/167 
gene set modules) as well as our gliomasphere data set (50/186 gene set modules).  To identify 
some potential target metabolic pathways, we used a cut-off enrichment value of 1.2. Even with 
this liberal cut-off we only identified four modules that were enriched in IDH1 mutant cells in both 
data sets.  Of these four, the “Homologous Recombination” and “Nucleotide Base Excision 
Repair” modules were selected for further study due to the clinical relevance in terms of response 
to radiation. In contrast, there were 35 modules that were enriched in IDH WT cells (Figures 1 and 
2). The “Pentose Phosphate Pathway” and “Amino Sugar and Nucleotide Sugar Metabolism” were 
selected for further study to determine if IDH1 WT cells are in fact more dependent on the de novo 
pathway of nucleotide synthesis.  
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Figure 1. KEGG Gene Set Enrichment Analysis. Plot of expression data from TCGA 
(167 KEGG modules) and our gliomasphere dataset (186 KEGG modules). Each KEGG module 
was assigned a normalized enrichment score (NES) in either the IDH1 mutant or IDH1WT group. 
Each blue dot represents a different module. The enrichment score for a particular module in the 
TCGA data is plotted along the X-axis and that associated with the gliomasphere dataset for the 
same module is plotted on the Y-axis. Thus, a module that is highly enriched in IDH1 mutants 
compared to wildtype in both datasets would be in the upper right corner and modules highly 
enriched in IDH wildtype in both datasets would be in the lower left hand corner. Differentially 
enriched modules (NES > 1.2), listed on the right, were identified as potential candidates for 
further investigation. 
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Figure 2: KEGG gene set enrichment analysis of IDH1 mutant and wildtype 
gliomaspheres. Thirty-five modules were enriched in IDH wildtypes compared to 4 modules 
in IDH1 mutants. 
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 Metabolic Profile- To assess the differences found in the expression analysis, and to 
investigate any further metabolic differences between groups, a cohort of IDH WT and IDH1 
mutant lines were selected for further study. Key mutations and CNVs of the 5 IDH1 mutant 
cultures and 3 IDH WT cultures that were most intensively studied are listed in Figure 3. Of note, 
4 of 5 of our IDH mutant cultures had pathogenic TP53 mutations and only one (BT142, obtained 
from ATCC) was 1p/19q co-deleted (Figure 3). Sample 322 was lost prior to detailed analysis, but 
clinical cytogenetics of the primary tumor demonstrated that it was not 1p/19q co-deleted, despite 
it being an oligodendroglioma. 
 
Figure 3: Patient-derived gliomasphere culture characteristics. Relevant patient 
information and clinical characteristics for the primary, patient-derived gliomasphere cultures used 
in this study. Summary of selected copy-number alterations and mutations are also shown. 
 
Culture	
ID	
PaDent	
Age	
PaDent	
Sex	 Diagnosis	 Treatment	
IDH1		
Status	
1p/19q	
co-
deleted	 EGFR	 TP53	 PTEN	 ATRX	 CDKN2A	
HK211	 41	 F	 Secondary	GBM	 N/A	
p.R132H/
p.V178I	 No	
	
vIII	
p.N235S/
p.Y234C	
HK213*	 39	 M	 Secondary	GBM	 XRT,	TMZ	 p.R132H	 No	 p.P250L	
HK252*	 40	 M	 Secondary	GBM	 XRT,	TMZ	 p.R132H	 No	 p.P250L	
HK322	 37	 F	
Oligodendrogli-
oma	Grade	II	 N/A	 p.R132H	 No	
CN	
Unknown	
CN	
Unknown	
CN	
Unknown	
CN	
Unknown	
CN	
Unknown	
BT142**	 38	 M	
Oligoastrocytom
a	Grade	III	 N/A	 p.R132H	 Yes	 p.I50fs	
HK157	 54	 F	 Primary	GBM	 N/A	 WT	 No	 WT	
HK301	 65	 M	 Primary	GBM	 N/A	 WT	 No	
	
vIII	 WT	
HK308	 50	 F	 Recurrent	GBM	
XRT,	TMZ,	
Avasen	 WT	 No	
CN	
Unknown		
(vIII)	
CN	
	Unknown		
(p.A161T)	
CN	
Unknown	
CN	
Unknown	
CN	
Unknown	
*Diﬀerent	reseceons	from	same	paeent	
Supplementary	Table	1.		
**Obtained	from	ATCC	 CN	Gain	 CN	Loss	(-1)	 CN	Loss	(-2)	
Copy	Number	(CN)	
vIII-	EGFR	variant	III	mutant	
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A cohort of 18 IDH WT and 5 IDH1 mutant cultures were subjected to a panel of metabolic 
measurements including glucose uptake, glutamine uptake, and lactate production rates. Glucose 
uptake rate was significantly higher in IDH WT cells although there was no significant difference 
in the lactate production to glucose uptake ratio, suggesting that both cohorts are highly glycolytic. 
The net glutamine uptake rate for all cells tested was near zero (Figure 4A-C). Consistent with 
these differences in glucose uptake, IDH wildtype cells grew faster than IDH1 mutant cells (Figure 
5). 
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Figure 4. Metabolic profile of IDH1 mutant and wildtype cells.   A-C. Quantification 
of glucose and glutamine consumption as well as the ratio of glucose consumed to lactate 
produced. Measurements were acquired using NOVA analysis (N= 18 IDH WT and 5 IDH1 
mutant). Statistical significance was determined by Student’s t-test. D. Clustering of three IDH1 
mutant and three IDH wildtype lines according to LC-MS glucose labeling (IDHWTs: blue, IDH1 
mutants: red). A glucose labeling index for each of the 159 metabolites analyzed was calculated 
for all 6 cell lines followed by non-hierarchical clustering analysis. Each line was run in triplicate 
and all samples are shown. E. Quantification of glucose labeling among nucleotide precursors by 
group. Relative amounts of metabolites were calculated by summing up all isotopologues of a 
given metabolite and normalized to the internal standard and cell number. 
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Figure 5: IDH wildtype cells show faster growth rate compared to IDH1 mutant 
cells. Six IDH wildtype and five IDH1 mutant gliomasphere cultures were assessed for 
proliferation rate by flow cytometry using carboxyfluorescein succinimidyl ester (CFSE). 
(P<0.05). 
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To further define the different utilization of these metabolites, we performed LC-MS on 3 
IDH WT (HK157, HK301, and HK308) and 3 IDH1mutant (HK213, HK252, and HK322) lines 
with both fully labeled 13C glucose and fully labeled 13C glutamine.  We then defined a single 
percent label for each metabolite and performed hierarchical clustering to identify if these six cell 
lines naturally partitioned into groups.  Consistent with the observed differences in glucose uptake, 
IDH1 mutant and IDH WT samples partitioned into separate groups when assessed for glucose 
labeling (Figure 4D). Applying hierarchical clustering to the samples according to glutamine 
labeling or total metabolite amount did not distinguish the samples into distinct groups. 
 Since glucose labeling could distinguish between IDH1 mutant and IDH WT samples, we 
performed t-tests and compiled a list of all metabolites that had an uncorrected p-value<0.05.  
Thirty-two metabolites fulfilled this criterion of differential glucose labeling. Of these 32 
metabolites, there was a significant over-representation of nucleotide precursors (9/32 chi-square 
p<0.007).  Interestingly, all of the nucleotide precursors showed increased glucose labeling in the 
IDH WT group (Figure 4E, Figure 6).   
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Figure 6: Glucose labeling of metabolites.  Glucose fractional contribution was computed 
for all 159 metabolites.  Metabolites that were significantly different between groups (uncorrected 
t-test p<0.05) are shown here.  
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 De Novo versus Salvage Nucleotide Synthesis- Because our gene expression and 
metabolomics results are consistent with elevated nucleotide metabolism in IDH WT cells, we 
decided to investigate further whether IDH WT cells are more dependent on de novo nucleotide 
synthesis than IDH1 mutant cells. We profiled the de novo and salvage contribution to 
deoxycytidine triphosphate incorporation into newly replicated DNA using labeled 13C glucose (to 
denote de novo) and labeled [13C9,15N3]dC (to denote salvage). Using the same set of three IDH 
WT lines and three IDH1 mutant lines we found that while all samples utilized both pathways, the 
IDH WT samples used primarily de novo synthesis while the IDH1 mutant samples used both 
pathways relatively equally (Figure 7A-B).  To identify if this difference had functional relevance, 
we utilized high levels of deoxythymidine (dT), an inhibitor of the de novo pathway125 to determine 
if there is any differential response between the two groups. Predicting that this inhibitor would 
have an effect on the ability of cells to pass through S-phase, we treated cells for four days (~1 
doubling time) with dT and then performed cell cycle analysis using DAPI.  All cell lines showed 
an increase in the number of cells in S phase; however, in the IDH1 mutant samples, cells were 
better able to pass through S phase and proceed with cell division.  In contrast, at the end of the 
four-day treatment period almost all IDH wildtype cells were found in S phase (Figure 7C). 
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Figure 7. IDH1 mutant cells utilize de novo and salvage pathways for nucleotide 
biosynthesis. A-B. Quantification of de novo nucleotide synthesis and salvage pathway 
utilization by LC-MS with labeled glucose and nucleotides. A shows the relative contribution of 
each pathway plotted in bar graph format, while B shows the same data plotted 2 dimensionally. 
Error bars represent +/- STDEV. C. Cell cycle analysis by flow cytometry (DAPI) following four-
day treatment with 1mM deoxythymidine (dT) or control (Left: distribution of cells in G1, S-phase, 
and G2; Right: representative histograms of cell cycle distribution for IDH1 mutant and WT 
cultures following dT treatment).  
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 DNA repair in response to radiation- Having discovered that GSEA expression analysis 
accurately predicted that IDH1 mutant cells are less dependent on de novo nucleotide synthesis 
than are the IDH wildtype cells that we studied, we next turned to the modules that we found to be 
enriched in IDH1 mutant cells, namely modules involved with DNA repair and cellular response 
to radiation.  Using a comet assay we first tested whether there was a difference in the amount of 
DNA damage incurred from a given dose of radiation and how quickly that DNA was repaired. 
For these experiments, we studied two of our IDH1/TP53 mutant lines as well as BT142, a highly 
studied IDH1 mutant that is 1p/19q-co-deleted but that also bears a TP53 mutation126, 127.  At a 
dose of 10 Gy, significantly more IDH WT cells showed signs of DNA damage as compared to 
IDH1 mutant cells at all time points tested (Figure 8A-B). In IDH1 mutant cells, DNA damage 
peaked immediately after exposure to radiation, but that damage was largely repaired within four 
hours.  Damage in IDH wildtype cells peaked after the first hour post-radiation and followed a 
similar trend with regard to repair. To examine repair dynamics, we next restricted our focus only 
to those cells with sustained measurable damage (comet tails) and then calculated tail moment 
length at different time points (0, 60, 120, and 240 minutes) to assess which group more efficiently 
repairs DNA. Again, the IDH1 mutant cultures showed significantly less initial damage following 
radiation and were able to resolve DNA breaks more quickly (Figure 8C). However, there was no 
significant difference in DNA damage between IDH1 mutant and wildtype cells by the final time 
point of the assay. 
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Figure 8. IDH1 mutant cells show diminished vulnerability to radiation. A-C. 
Assessment of DNA damage and repair by comet analysis following irradiation (10Gy). A. 
Representative images of cells following comet assay. White arrows indicate cells with comets. B. 
Graph showing the percent of cells with comets. Comet number was calculated for each line 
individually and then averaged by group. C. Tail moment length for each comet was calculated as 
the length from the center of the comet head to the center of the tail. Tail moment length was 
calculated for each line individually and then averaged by group. Significance levels were 
calculated by ANOVA followed by posthoc t tests. Asterisks denote P<0.05, Error bars: +/- SEM. 
D. Quantification of the effects of increasing doses of radiation (0, 2, 6, and 10Gy) on culture 
growth as described in the Methods section. Graphs represent cell counts normalized to non-
irradiated controls. 
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 We assessed the extent of apoptotic cell death using the TUNEL assay but saw relatively 
low levels of TUNEL staining and no significant difference between the two groups (Figure 9). 
However, when we examined the ability of cells to grow after radiation we again found that IDH1 
mutant cells were better able to re-enter the cell cycle and divide as compared to IDH WT cells 
(Figure 8D).  
 
Figure 9: Radiation leads to low levels of TUNEL staining in gliomaspheres. Representative 
images and quantification of cells stained for TUNEL positivity four days after exposure to 
increasing doses of radiation. There is no significant difference between groups. Error bars 
represent +/- SEM. 
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 IDH1 mutant overexpression as a model for IDH1 mutant glioma- IDH1 mutant over-
expression in an IDH1WT background makes those cells more vulnerable to radiation113.  With 
our new result that endogenous IDH1 mutant cells are less vulnerable to radiation than the IDH 
WT cells tested, it appeared that the IDH1mutation itself was not the sole determinant driving the 
difference between these two groups. To further test this hypothesis, we over-expressed the IDH1 
mutant protein in an IDH WT background (HK308+IDH1mut) and pharmacologically inhibited 
the IDH1 mutant protein in an endogenous IDH1 mutant cell line (HK213+c227). We used LC-
MS to confirm 2-HG production and inhibition respectively (Figure 10). Once we confirmed the 
appropriate effects on 2-HG production, we repeated the glucose-uptake clustering analysis to see 
if this artificial IDH1 mutant line (HK308+IDH1mut) clustered with the IDH WT or the IDH1 
mutant groups (Figure 11A).  We found that the HK308+IDH1mut samples clustered with the IDH 
WT group and the HK213+c227 clustered with the IDH1mut group. More specifically, neither 
IDH1 mutant over-expression nor the c227 inhibitor led to a change in glucose labeling of 
nucleotide precursors (Figure 12).  This supports the hypothesis that the simple presence of IDH1 
mutant protein or 2-HG was not driving the difference between these two groups over the time 
frames investigated.   
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Figure 10: IDH1 mutant over-expression leads to high levels of 2-HG and the 
c227 inhibitor is an effective inhibitor of 2-HG formation. IDH wildtype 
gliomaspheres transduced with the IDH1 mutant enzyme (308+IDH1mut) and endogenous IDH1 
mutant cells treated with 5 uM c227 inhibitor (213+c227) for 24 hours are compared to their 
respective controls (308 and 213) for 2-HG levels as determined by LC-MS. Data represent the 
means +/- SEM of three replicates per condition. 
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Figure 11. IDH1 mutant enzyme activity does not completely define the IDH1 
mutant metabolic profile. A. Clustering of eight samples based on LC-MS glucose labeling 
as described in Figure 4. Analysis includes the same cohorts of IDH1 mutant and wildtype cultures 
with the addition of IDH1 mutant over-expression in an IDH WT line and inhibition of the 
endogenous mutant enzyme (308+IDH1mut and 213+c227 respectively). B, C. Quantification of 
glutamine and glucose consumption with IDH1 mutant overexpression and inhibition. D. 
Contribution of glucose and glutamine to 2-HG production in endogenous and transduced IDH1 
mutants. E. Effects of IDH1 mutant over-expression on glutamine and TCA cycle intermediates 
quantified using LC-MS. P<0.05 for all 7 metabolites shown. Error bars denote +/- SEM. 
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Figure 12: IDH1 mutant enzyme does not affect glucose labeling of nucleotide 
precursors. Cells were treated and analyzed as described for Figure 6 in order to determine the 
percent labeling of nucleotide precursors. There is no significant difference when comparing IDH1 
mutant over-expression or endogenous mutant inhibition to their respective controls. 
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We next investigated what effect the presence of the IDH1 mutant protein had on cellular 
metabolism.  We examined the effects on glutamine and glucose consumption and found that 
neither the addition nor inhibition of the endogenous IDH1 mutant enzyme influenced the 
consumption of either metabolite (Figure 11B-C).  This was a surprising result given that the 
expression of the IDH1 mutant enzyme leads to production of high levels of 2-hydroxyglutarate 
and presumed consumption of alpha-ketoglutarate.  To investigate this further, we used LC-MS 
tracing with labeled glucose and glutamine to determine how the cell makes 2-HG.  Both 
endogenous IDH1 mutants as well as our over-expression model primarily used glutamine to make 
2-HG (Figure 11D). However, given that we did not observe an increase in the amount of 
glutamine consumption with the addition of the IDH1 mutant gene, we hypothesized that the cells 
may be depleted of glutamine.  Consistent with this prediction we saw significantly lower levels 
of glutamine as well as all TCA cycle intermediates when the IDH1 mutant gene was over-
expressed (Figure 11E).  In a recent study, Li et al. found that elevating 2-HG levels leads to a 
significant accumulation of succinate with corresponding decreases in fumarate and malate128. 
Interestingly, we observed decreased levels of succinate and increases in fumarate and malate with 
2-HG inhibition (c227) in an endogenous IDH1 mutant line (HK213). However, this did not 
accurately reflect the differences between endogenous IDH1 mutant and IDH wildtype cells which 
had roughly comparable levels of glutamine and TCA cycle intermediates (Figure 13), suggesting 
that the IDH1 mutation is well-compensated for in the cells that carry it.  
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Figure 13: Effects of pharmacologic inhibition of the IDH1 mutant enzyme on 
TCA cycle intermediates. Cells were analyzed as described in Supporting Figure S5.  Left: 
Metabolites with significantly different percent glucose labeling of metabolites in the endogenous 
IDH1 mutant line 213 treated with c227 inhibitor or control (p<0.05). Right: Percent labeling from 
endogenous IDH1 mutant and IDH wildtype groups for metabolites that were not significantly 
different. 
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In order to further identify potential differences between the endogenous IDH1 mutant and 
overexpression models, as well as to help clarify differences between our observations of radiation 
sensitivity from previous reports113, we repeated our radiation experiments on HK308 with and 
without over-expression of the IDH1 mutant enzyme. Over-expression of the mutation in this IDH 
wildtype line resulted in greater DNA damage and decreased repair immediately following 
radiation (Figure 14A-C). These results are contrary to what was observed when comparing 
endogenous IDH1 mutants to IDH wildtype cell lines (Figure 8). IDH1 mutant over-expression 
did, however, result in better growth following radiation (Figure 14D). One possible explanation 
for this is that exogenous expression of the IDH1 mutant enzyme in HK308 leads to significantly 
slower growth and this may give the cell more time to repair any DNA damage before re-entering 
the cell cycle. 
Finally, we examined the effect of the IDH1 mutant enzyme on reactive oxygen species 
(ROS) levels. Interestingly, studies have reported mixed results regarding the effect of the IDH1 
mutation on ROS with different results in different cell types129, 130.  We found that the endogenous 
IDH1 mutant lines had significantly higher ROS levels than the IDH WT lines (Figure 15A). This 
appears to be due to the IDH1mutation itself, because when we over-expressed the IDH1 mutant 
enzyme in HK308, the ROS levels increased significantly (Figure 15B).  
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Figure 14. IDH1 mutant over-expression does not accurately mimic the DNA 
repair capacity of endogenous mutants. A-C. Assessment of DNA damage and repair by 
comet analysis following radiation (10Gy) A. Representative images of cells following comet 
assay. White arrows point to cells with comets. B. Graph shows the percent of cells with comets. 
Comet number was calculated for each line individually and then averaged by group. C. Tail 
moment length for each comet is calculated as the length from the center of the comet head to the 
center of the tail. Tail moment length was calculated for each line individually and then averaged 
by group. D. Quantification of the effects of increasing doses of radiation (0, 2, 6, and 10Gy) on 
culture growth as described in the Methods section. Graphs represent cell counts normalized to 
non-irradiated controls. Significance levels were calculated by ANOVA followed by posthoc t 
tests. Asterisks denote P<0.05, Error bars: +/- SEM. 
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Figure 15. IDH1 mutant enzyme leads to higher ROS levels. A. Histogram displaying 
ROS levels of 3 IDH1 mutant and 3 IDH1wildtype gliomaspheres measured using flow cytometry 
(CellROX Green). B. Similar ROS analysis of an IDH WT line (HK308) with and without IDH1 
mutant over-expression (CellROX Deep Red). Results shown are from individual experiments. 
Three replicates yielded identical findings. 
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Discussion 
 
 Many groups have attempted to determine the effect of the IDH1mutation on host cells as 
a way to discover metabolic vulnerabilities that may be exploited for therapy.  Endogenous IDH1 
mutant glioma cells are difficult to grow and maintain in culture—indeed, we lost one line during 
the process of these experiments--and thus the first experiments to determine the effect of the 
IDH1mutation on cells involved exogenous over-expression of the IDH1 mutant gene in an IDH 
WT background and performing mass spectroscopy to find differences in the levels of the various 
metabolites119, 127, 131, 132, 133. While many of these studies had overlapping findings (e.g. a decrease 
in glutamine and glutamate levels), other findings were more variable and seemed to depend on 
the cell model being used.  Additionally, many of these in vitro differences did not translate to ex 
vivo patient tumor tissue134. 
 Consistent with the aforementioned studies we also saw a decrease in glutamine and 
glutamate with exogenous IDH1 mutant over-expression. However, there was no difference in 
glutamine, glutamate, or any TCA cycle intermediates between IDH wildtype cells and 
endogenous IDH1 mutant cells.  This suggests that endogenous IDH1 mutant cells may be able to 
compensate for many of the effects of the IDH1 mutant enzyme itself. One possible explanation 
for this is that IDH1 mutant glioma cells and IDH wildtype glioma cells are derived from different 
cell types with different properties. However, it is also possible that given enough time, the 
exogenous IDH1 mutant model would also be able to compensate for the IDH1 mutant enzyme 
and increase its glutamine and glutamate levels. 
 Another approach to determine the metabolic effect of the IDH1mutation on glioma cells 
is to inhibit the IDH1mutation in an endogenous IDH1 mutant line.  Both the current study and the 
prior study of Tateishi et al114 found a mixed effect of the IDH1 mutant inhibitor on TCA cycle 
 45 
intermediates, with citrate being significantly increased in both studies.  In our study, we used a 
relatively short incubation period (24hr) with the c227 inhibitor in order to isolate the differences 
in metabolic flux from the changes in gene expression that are associated with 2-HG and aberrant 
methylation. Although the Tateishi study did not find any significant changes in global methylation 
with prolonged c227 inhibitor treatment, they did find an increase in NADH levels likely due to 
increased Naprt1 expression and NAD synthesis.  We did not see this change over our shorter time 
course and, in fact, we saw decreased NADH levels with c227 treatment.  
 A current challenge in IDH mutant research stems from the variability in methodological 
approaches used which can significantly alter findings. Identifying potential shortcomings of each 
will greatly improve the reliability of results. For example, by restricting comparisons to purely 
isogenic cell lines with or without IDH1 mutant enzyme over-expression or inhibition, the 
conclusions are limited to the effect of the IDH1 mutant enzyme itself and ignore differences 
between IDH1 mutant and IDH wildtype tumors that may be independent of the IDH1 mutation.  
Furthermore, metabolites do not act independently but function as parts of larger pathways.  Using 
only the total cellular levels of various metabolites, it is difficult to draw any conclusions about 
particular pathways. In this study we utilized multiple methods to identify cell-type specific 
vulnerabilities. By using expression data and metabolic tracing studies we were readily able to 
distinguish several pathways as well as labeling patterns that clearly distinguished IDH1 mutant 
from IDH wildtype cells.  This distinctive metabolic signature was intrinsic to the cell itself, was 
retained even with pharmacological inhibition of the IDH1 mutant enzyme, and was not seen in 
the exogenous over-expression model. 
 Further evidence of cell culture model variability between IDH mutant studies can be seen 
from two additional reports published during the preparation of this manuscript, Sulkowski et al. 
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and Lu et al.135, 136, which demonstrated a diminished capacity for DNA damage repair in IDH1 
mutant cells citing deficiencies in homologous recombination and compromised PARP-mediated 
DNA repair. We observed greater DNA damage and a similar decreased capacity for DNA repair 
only when using an IDH1 mutant over-expression model. In contrast, our results indicate greater 
DNA repair capacity in IDH1 mutant cells following radiation. One potential explanation could 
be that our cultures represent only a subset of IDH1 mutant tumors. Most, if not all, contain 
endogenous IDH1 R132H mutations and mutant TP53. Furthermore, the IDH wildtype GBM 
cultures that were selected as controls could influence the differences observed. While both of 
these prior studies utilize exogenously transduced IDH mutations, which may have different 
characteristics, one report did also utilize glioma cells with endogenous mutations for some of 
their key experiments135. However, it is not clear whether these mutant lines are similar to ours 
with respect to their other mutations. Furthermore, the endogenous mutant cultures from the prior 
report were propagated in serum, while ours are continuously maintained in serum-free conditions. 
The differences amongst these studies have important ramifications for therapy. If, as we propose, 
IDH1 mutants have a greater capacity for DNA repair following radiation, then radiation therapy 
may have diminished efficacy. Further study will be required to resolve these differences. 
 Many of the clinical trials that guide current treatment protocols for glioblastoma were 
conducted before the discovery of the IDH mutation and thus included a majority of IDH wildtype 
and a minority of IDH mutant patients. With evidence mounting that IDH mutant gliomas have 
very different cellular characteristics, it is unclear whether the results of these trials can be 
generalized to IDH mutant tumors. In particular, the results of this study show that IDH1 mutant 
gliomas are less vulnerable to radiation-induced DNA damage which draws into question the 
efficacy of radiation therapy for this subset of tumors.  This result was surprising when combined 
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with the fact that exogenous IDH1 mutant over-expression makes cells more vulnerable to 
radiation113, and that the IDH1 mutant enzyme significantly increases the amount of reactive 
oxygen species in the cell. While the cytotoxic and cytostatic mechanisms of radiation are multi-
factorial, one of the main mechanisms is DNA damage through the indirect production of free 
radicals137. One possible explanation for the decreased DNA damage seen in IDH mutant cells 
following radiation is that in order to survive this mutation, IDH mutant cells must develop 
buffering mechanisms against high levels of reactive oxygen species. This adaptation in turn could 
make them more resistant to radiation induced DNA damage. 
 The clinical evidence for the efficacy of radiation in IDH1 mutant gliomas is mixed.  In 
one study IDH1 mutant tumors seemed to show a better radiographic response following 
radiation138. However, another trial found that for supratentorial low grade gliomas (of which the 
majority are likely IDH-mutant) high dose radiation had worse survival than low dose 
radiation139.  It is possible that both findings are correct and that radiographic response may not 
correlate with clinical survival. Conversely, it is possible that IDH mutant tumors are maximally 
sensitive to low dose radiation and higher doses do not provide any further benefit.   
 Our studies of nucleotide metabolism have potential implications for therapeutics. The 
availability of nucleotides for DNA synthesis can be a rate-limiting step in cellular proliferation140. 
Nucleotides are synthesized through either de novo or salvage pathways. Pharmacologically, the 
de novo pathway can be inhibited by high concentrations of dT and the salvage pathway can be 
inhibited by a novel class of compounds125. Our data suggest that IDH1 mutant tumors, in contrast 
to the majority of GBM, utilize this salvage pathway and would hence require both pathways to 
be inhibited in therapeutic strategies employing inhibition of nucleotide biosynthesis. 
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 A limitation to the current study is that, while gene expression studies are performed using 
both cultured cells and data derived directly from IDH mutant tumors in vivo, our functional results 
are obtained from in vitro studies. Very few studies have investigated a spectrum of IDH mutant 
gliomas in vivo. This is undoubtedly due to the difficulty in propagating these cells in xenograft 
models. Although not shown, the cells we have utilized did not form xenografts in 
immunodeficient mice, either in the brain or subcutaneously. The reasons for this are unknown but 
suggest that the establishment of tumors from endogenous IDH1 mutants requires host-derived 
factors that are not present in our model systems. While our findings present novel hypotheses and 
avenues for future studies, some caution must be taken prior to applying our results directly to 
clinical trials. 
 With evidence mounting that IDH mutant gliomas constitute a distinct subclass that follows 
an independent path of tumorigenesis141, we endeavored to characterize metabolic differences 
between IDH1 mutant and IDH wildtype gliomas.  Our data are consistent with this concept and 
provide evidence that some of the distinctions may not be directly related to the IDH1 mutation 
itself. Furthermore, our data suggest that while IDH1 mutant gliomas may have a less malignant 
phenotype, they may also be relatively resistant to certain therapies, including radiation. 
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Methods 
 Collection of in vitro cultures- Samples were collected under institutional review board-
approved protocols and graded by neuropathologists. We previously reported on gene expression 
analysis in these samples in all except one of the IDH mutants124. IDH wildtype samples were all 
from GBM. Of the 7 IDH1 mutant cultures, 5 were from GBM, one from a grade III 
oligoastrocytoma and one from a grade II oligodendroglioma. Cultures were prepared as described 
previously124. Briefly, on the day of resection, samples were digested with papain.  Acellular debris 
was removed and remaining cells were incubated in gliomasphere media (DMEM/F12 
supplemented with B27, penicillin/ampicillin, heparin, EGF and bFGF) for several days until 
spheres began to form.  Frozen stocks were made at passage 5 to maintain cells at low passage. 
One IDH1 mutant line, BT142, was obtained through ATCC126, 127. Relevant information 
pertaining to the cultures used for in vitro experiments is summarized in Figure 3, which provides 
the characteristics of the patients and the tumor as reported by neuropathologists as well as data 
from comparative genomic hybridization and whole exome sequencing in the samples for which 
it was available. The majority of experiments were performed using the same 3 IDH WT lines 
(HK157, HK301, and HK308) and 3 IDH1 mutant lines (HK213, HK252, and HK322). Prior to 
the completion of data collection, the HK322 culture was lost. Therefore, two additional IDH1 
mutant lines (BT142 and HK211) were included for the radiation experiments.  
 
 Whole exome sequencing and mutation analysis- Genomic DNA was extracted and 
fragmented by sonication using the Covaris acoustic disruptor (model E210, Covaris Inc.)  to 
achieve an average fragment size of 200 base pairs. 200 ng of DNA from each sample were used 
for the construction of DNA libraries using Kapa Hyper DNA library prep kits and matched dual 
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index adapters (Integrated DNA Technologies). Exome capture was performed using the 
Nimblegen SeqCap EZ Exome enrichment kit. Sequencing was performed on an Illumina HiSeq 
4000 following the manufacturer’s instructions. 65-70 million 120-base, paired-end reads were 
obtained per sample on average, with a 50x average depth of coverage within the targeted exome. 
Raw image files were processed with the Illumina CASAVA 1.8 software (Illumina, San Diego, 
CA).  
 Whole exome sequencing was analyzed using the Genome Analysis Toolkit (GATK)142 
pipeline. Briefly, short reads were aligned using the Burrows-Wheeler Aligner (BWA)143. 
SAMtools was used to convert between SAM and BAM file format, and Picard tools to sort 
alignments and mark duplicates. Variants were called using the GATK HaplotypeCaller function 
with the following parameters: variant index parameter 128000; variant index type LINEAR; nda; 
maxAltAlleles 4; ERC GVCF; contamination 0.02. ANNOVAR144 was used to annotate variants. 
 
 Copy number variation (CNV) analysis- DNA libraries were hybridized onto Affymetrix 
CytoScanHD arrays. We first processed the raw intensity CEL files using the R package affy2sv145 
to generate B-allele frequency (BAF) and log R ratio (LRR) values. Secondly, we used the 
PennCNV software (parameters: exome HMM model with gcmodel adjustment, filtered by 10 
SNPs minimum 10 and with region length longer than 50k)146, the R package GenoCN 
(parameters: cnv-only snpInfo$PFB>1; outputSNP 1; outputSeg TRUE)147, and the R package 
Rawcopy (default parameters)148 for CNV inference. CNV calls were obtained by integrating the 
output from all callers. 
 
 Gene set enrichment analysis- RNA was purified from 59 patient-derived gliomasphere 
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cultures and hybridized to Affymetrix U133 Plus 2.0 arrays. For KEGG-based analysis, we 
collapsed gene expression probes based on enzyme activity (Enzyme Commission numbers [EC]) 
rather than on gene identity to avoid unequal representation of equivalent enzymatic function 
within pathways, thus emphasizing potential flux through the network.  The metric used for gene 
ranking was the signal to noise ratio (SNR) between the IDH1 mutant and IDH1WT samples.  The 
metric was calculated for all candidate probesets of each gene or enzymatic activity and the 
probeset with maximum absolute metric value was retained.  Probeset annotation was based on 
UniGene build #201 and UniGene identifiers were mapped to each EC using the gene names 
provided by KEGG. Pathways with fewer than three or greater than 500 nodes represented by the 
data were excluded from the analysis.  This resulted in 167 KEGG modules in the TCGA dataset 
and 186 modules in the gliomasphere data set. 
 
 Glucose/Glutamine Uptake- 200,000 cells were plated in 3ml of gliomasphere media and 
allowed to grow for 24 hours.  The cells were spun down and counted, and glucose and glutamine 
levels in the used media were measured using a NOVA Bioanalyzer and compared to blank 
control149, 150, 151.  To evaluate the effects of IDH1 mutant inhibition on glucose/glutamine uptake, 
5uM of c227 was added to the culture 24 hours before being harvested. 
 
 Cell proliferation studies (CFSE)- Cell proliferation of endogenous IDH1 mutant and IDH 
wildtype cultures was assessed using CFDA SE (CFSE; carboxyfluoresceindiacetate, succinimidyl 
ester) cell tracer kit (Invitrogen) as described previously152. Briefly, spheres were dissociated with 
Accumax (Innovative Cell Technologies), stained with CFSE according to manufacturer 
suggestions, and grown for 5 days under normal gliomasphere conditions at a density of 100,000 
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cells/mL. Preparation for FACS analysis was performed according to manufacturer guidelines 
using 4% paraformaldehyde as a fixative. Following FACS acquisition, Proliferation Wizard Basic 
Model was used to assess proliferative populations within each sample and to generate average 
division times.  
 
 Liquid chromatography–mass spectrometry (LC-MS)- Cells were cultured for 24 hours and 
rinsed with PBS, and either unlabeled media, 50% 13C-glucose labeled media, or 50% 13C-
glutamine labeled media was added.  After 24 hours, cells were rinsed with ice-cold 150mM 
NH4AcO (pH 7.3), followed by addition of 400ul cold methanol and 400ul cold water. Cells were 
transferred to an Eppendorf tube, and 10 nmol norvaline (Sigma-Aldrich, N7502) as well as 400ul 
chloroform were added to each sample.  For the metabolite extraction, samples were vortexed for 
5 minutes on ice and spun down, and the aqueous layer was transferred into a glass vial and dried.  
Metabolites were resuspended in 70% ACN and 5 ul loaded onto a Phenomenex Luna 3u NH2 
100A (150 x 2.0 mm) column.  The chromatographic separation was performed on an UltiMate 
3000 RSLC (Thermo Scientific) with mobile phases A (5 mM NH4AcO pH 9.9) and B (ACN) and 
a flow rate of 300 ul/min.  The gradient ran from 15% A to 95% A over 18 min, 9 min isocratic at 
95% A, and re-equilibration for 7 min.  Metabolite detection was achieved with a Thermo 
Scientific Q Exactive mass spectrometer run in polarity switching mode (+3.0 kV/-2.25kV).  
TraceFinder 3.3 (Thermo Scientific) was used to quantify metabolites as the area under the curve 
using retention time and accurate mass measurements (< 3ppm).  Relative amounts of metabolites 
were calculated by summing up all isotopologues of a given metabolite and normalized to the 
internal standard and cell number.  Clustering analysis was done in R. 
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 Metabolic Tracing using combined liquid chromatography and tandem mass spectrometry 
(LC-MS/MS)- Cell lines were grown in gliomasphere media supplemented with fully-labeled 13C-
glucose and 13C9,15N3-dC.  The cells were allowed to grow for 48 hours at which point they were 
harvested and lysed.  Genomic DNA was extracted using the Quick-gDNA MiniPrep kit (Zymo 
Research, D3021) and hydrolyzed to nucleosides using the DNA Degradase Plus kit (Zymo 
Research, E2021), following manufacturer-supplied instructions. In the final step of DNA 
extraction, 50 µL of water was used to elute the DNA into 1.5 mL Eppendorf tubes. A nuclease 
solution (5 µL; 10X buffer/DNA Degradase Plus™/water, 2.5/1/1.5, v/v/v) was added to 20 µL of 
the eluted genomic DNA in an HPLC injector vial. The samples were then incubated overnight at 
37 ºC. Samples (20 µL) were injected onto a porous graphitic carbon column (Thermo Fisher 
Scientific Hypercarb, 100 x 2.1 mm, 5 µm particle size) equilibrated in solvent A 
(water/acetonitrile/formic acid, 95/5/0.2, v/v/v) and eluted (200 µL/min) with an increasing 
concentration of solvent B (acetonitrile/water/formic acid, 90/10/0.2, v/v/v) using min/%B/flow 
rates (µL/min) as follows: 0/0/200, 5/0/200, 10/15/200, 20/15/200, 21/40/200, 25/50/200, 
26/100/700, 30/100/700, 31/0/700, 34/0/700, 35/0/200. The effluent from the column was directed 
to the Agilent Jet Stream ion source connected to the triple quadrupole mass spectrometer (Agilent 
6460) operating in the multiple reaction monitoring mode using previously optimized settings. The 
peak areas for each nucleosides and nucleotides (precursor→fragment ion transitions) at 
predetermined retention times were recorded using the software supplied by the instrument 
manufacturer (Agilent MassHunter). To evaluate the effects of IDH1 mutant inhibition on glucose 
glutamine labeling 5uM of c227 was initially added to the culture and then re-added following 
PBS wash. 
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 Deoxythymidine (dT) treatment- To evaluate the effects of nucleotide synthesis inhibition, 
a group of cells were grown in gliomasphere media and subjected to 1mM dT treatment and 
allowed to grow for four days.  At this point the cells were harvested, stained with DAPI, and 
subjected to flow cytometry analysis to determine cell cycle distribution.  
 
 Radiation- To determine the extent of DNA damage following radiation, gliomaspheres 
were dissociated, plated at 1x105 cells/mL, and subjected to a 10Gy dose of radiation using an X-
ray irradiator (Gulmay Medical, Atlanta, GA) (5.519 Gy/min; 250 kV; a 4-mm Be, a 3-mm Al, and 
a 1.5-mm Cu filter). Neutral-buffered Oxiselect Comet Assay Kit (Cell Biolabs) was used to assess 
DNA damage according to manufacturer’s instructions. Radiation-induced apoptosis was 
measured at four days after treatment using TUNEL staining.  To determine effects of growth 
following radiation, cell lines were plated at 2x105 cells in 3ml of gliomasphere media. They were 
then subjected to the indicated doses of radiation (0Gy, 2Gy, 6Gy, and 10Gy) and allowed to 
recover for a minimum of 4 days.  When the control group of each cell line was ready to be 
passaged, all samples from that line were dissociated with Accumax (Innovated Cell Tech.), 
counted on a Countess Automated Cell Counter (Invitrogen, C10227) using 0.4% trypan blue, and 
compared to the non-irradiated control group. Each bar on the graph (dose of radiation) is the 
average percent of control based on a minimum of 3 independent replicates (Error bars= +/- SEM). 
   
 IDH1 mutant over-expression/ROS Measurement- cDNA for the IDH1 mutant gene 
(R132H) was cloned into a lentiviral vector and transfected into HK308 cell line. This vector 
encodes a murine orthologue and was found to maintain better and more consistent expression of 
the mutant protein and 2-HG than a human vector (data not shown).  500,000 IDH1WT cells were 
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dissociated and plated in 3ml of neurosphere mediated, infected with the lentivirus, and allowed 
to grow for 2 weeks.  The cells were sorted for GFP and again allowed to grow and form spheres.  
All experiments were done within 6 weeks of infection. Over-expression of the IDH1 mutant 
protein was confirmed by western blot and 2-HG measurement.  IDH1 mutant and IDH wildtype 
cells were allowed to grow in gliomasphere media.  They were then collected, stained with 
CellROX reagents (Thermo Fisher), and analyzed by flow cytometry.  The total ROS level was the 
integration of the area under the curve as previously described153.  
 
Statistical analysis- Statistical analyses were performed using the GraphPad Prism 
software. Sample comparisons and level of significance were determined using the ANOVA model 
and two-tailed Student’s t-tests where appropriate. All quantitative data presented are the mean +/- 
standard error of the mean (SEM) unless otherwise noted. Experiments were performed in 
triplicate, with calculation of 95% confidence interval and P values in relevant comparisons. 
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Chapter 3 
 
Metabolism of fatty acids and ketone bodies for growth by glioblastoma: 
Implications for Ketogenic Diet Therapy 
 
Abstract 
Glioblastoma (GBM) metabolism has traditionally been characterized by a primary 
dependence on aerobic glycolysis, prompting the use of the ketogenic diet as a potential therapy. 
Recent preclinical evidence, however, suggests that alternative metabolic pathways may serve as 
important contributors. In this study we evaluated the effectiveness of the ketogenic diet in GBM 
and assessed the role of fatty acid oxidation (FAO) in promoting GBM propagation. In vitro assays 
with U87 glioma cells revealed growth-promoting effects of both ketone body and fatty acid (FA) 
supplementation under physiological glucose conditions. An in vivo assessment of the unrestricted 
ketogenic diet (administered ad libitum) surprisingly resulted in increased tumor growth and 
decreased animal survival. These effects on tumor growth and survival are abrogated by FAO 
inhibition using shRNAs or CRISPR-based knockdown of carnitine palmitoyltransferase 1 
(CPT1), the rate limiting enzyme for fatty acid oxidation. Further in vitro assessment using primary 
GBM cultures revealed CPT1 functionality as well as decreased proliferation, increased apoptosis, 
and elevated mitochondrial ROS production with CPT1 inhibition with etomoxir. Liquid 
chromatography-mass spectrometry (LC-MS) metabolomic tracing with 13C-labeled fatty acids 
showed significant FA utilization within the TCA cycle that also extended throughout the GBM 
metabolome, indicating that FAO could be used for both bioenergetics and the production of key 
intermediates. Finally, an assessment of both IDH1 mutant and wildtype gliomasphere cell lines 
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revealed differences in FAO utilization. Altogether, these data highlight important roles for FA 
and ketone body metabolism that could serve to improve targeted therapies in GBM. 
 
Background 
Glioblastoma (GBM), the most aggressive and therapy resistant form of brain tumor, is 
traditionally characterized by its reliance on the Warburg effect. Under normal physiological 
conditions the healthy adult brain meets most of its energy demand by complete oxidation of 
glucose. This produces pyruvate which is then converted into acetyl-CoA for entrance into the 
TCA cycle to support the electron transport chain101. Thus, glycolysis and respiration remain 
tightly connected and result in more efficient ATP production with little lactic acid production. In 
contrast, the Warburg effect dramatically increases the rate of aerobic glycolysis and lactic acid 
production in the cytosol. While the benefits of this phenomenon are not completely understood, 
it has been posited that its main advantages are increased biomass production and facilitated 
invasion due to acidification of the microenvironment22. 
GBMs have been identified as highly reliant on aerobic glycolysis to the point that they are 
sometimes referred to as being “glucose addicted”. Several common signaling pathways found to 
be altered in GBM, such as PI3K-Akt-mTOR and Myc pathways, promote this phenotype by 
increasing expression of genes that allow cells to take up large amounts of glucose for increased 
glycolysis and lactate production101, 154, 155, 156. Alterations to these pathways are often associated 
with mutations common to GBM such as EGFR and PTEN. EGFR, an activator of PI3K, is 
amplified in ~40% of GBMs with approximately half of those tumors expressing the constitutively 
active EGFRviii variant16. The tumor suppressor protein PTEN, a potent PI3K antagonist, is also 
altered in 30-40% of GBMs19. Similar to EGFR amplification, loss of PTEN function by either 
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mutation or deletion results in hyperactivation of the PI3K/Akt signaling network. Despite these 
findings, little progress has been made therapeutically in targeting enzymes reported to regulate 
glucose metabolism in GBM.  
The interconnection between oncogenic signaling networks and metabolic pathways is 
complex in GBM. For example, while EGFR and PTEN mutations affect PI3K/Akt/mTOR 
activation, a major contributor to “glucose addiction”, this signaling node also acts as a master 
regulator for switching between metabolic utilization of glucose, glutamine, fatty acids, and 
ketones59,157,158,159. Mutations in isocitrate dehydrogenases (IDH) 1 and 2 are also commonly found 
in gliomas. Wildtype metabolic function of these enzymes is primarily restricted to the TCA cycle 
where they produce alpha-ketoglutarate through the oxidative decarboxylation of isocitrate. 
However, these enzymes often incur neomorphic gain-of-function mutations that result in the 
production of 2-hydroxyglutarate (2-HG)44, a proposed oncometabolite, along with widespread 
changes that extend far beyond the TCA cycle. The effects of IDH mutations have been attributed 
to altered glucose and nucleotide metabolism, DNA repair capacity, and reactive oxygen species 
(ROS) regulation, to name a few1,160,161.  Thus, the mutations present in any given tumor (such as 
EGFR, PTEN, and IDH1) may determine the extent to which it can adjust to declining substrate 
availability, pathway inhibition, or therapeutic insult. Reconciling mutational status with 
metabolic flexibility represents a critical step to establishing more effective metabolic therapies 
for GBM. 
The ketogenic diet (KD), which is a high fat, low carbohydrate, adequate protein diet has 
been proposed as a potential adjuvant therapy for a number of cancers including GBM162,83. With 
traditional diets, carbohydrates are plentiful and converted to glucose which then circulates to the 
brain as a major source of fuel. The KD limits carbohydrate availability and forces the production 
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of ketone bodies such as ß-hydroxybutyrate and acetoacetate in the liver. Once in the brain these 
ketone bodies are converted to acetyl-CoA for entrance into the TCA cycle. The ability of the brain 
to oxidize ketone bodies is well-established, with one report estimating that up to 60% of the 
human brain energy requirement can be matched by ketone body oxidation91. The therapeutic 
premise of the KD is therefore dependent on the hypothesis that reducing glucose availability will 
starve cancer cells of necessary nutrients without causing harm to healthy brain tissue. The degree 
to which GBM cells can oxidize ketone bodies, however, is not completely understood, with 
several preclinical studies using the KD in animal brain tumor models showing varying levels of 
success82, 163, 96.  
FAs participate in a number of cellular processes including signal-transduction, membrane 
synthesis, and energy storage. FAs are typically synthesized from excess glucose and stored within 
the body as triglycerides in adipose tissue; however, they are also generated and stored 
endogenously by highly proliferative tissues like cancers through de novo FA synthesis. The 
elevated production of fatty acids in cancer is often driven by oncogenic mutations themselves164. 
Increased PI3K/Akt signaling, which can occur through mutations to EGFR or PTEN, results in 
upregulation of SREBP-1-mediated fatty acid synthesis and cholesterol uptake165, 166, 167. Similarly, 
oncogenic KRAS upregulates FA synthesis through mTORC1 and SREBP-mediated activation of 
fatty acid synthase (FASN)168. These FAs can then be used for membrane biosynthesis or as 
bioenergetic molecules. When cells require additional energy, FAs can undergo fatty acid beta-
oxidation (FAO) within the mitochondria to generate acetyl-CoA to feed the TCA cycle and 
electron transport chain. In addition to ATP production, FAO also supports the production of a 
number of important cellular building blocks. For example, FA-derived citrate and malate can exit 
the TCA cycle to participate in the generation of both amino acid and lipid precursors79. FAO was 
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largely overlooked in the brain until recently, likely due to long-standing misconceptions that fatty 
acids (FAs) do not cross the blood brain barrier (BBB) and FAO does not take place. These 
misconceptions have since been dispelled and suggest that FAs play a large role in overall brain 
metabolism169, 66, 170, 67.  
 In this study we investigate the ability of GBM cells to utilize both ketone bodies and FAs 
to support tumor growth and survival, especially because of the mounting interest in the ketogenic 
diet as an adjuvant therapy. We determined that implementation of the KD (administered ad 
libitum) can actually promote GBM tumor growth, but that this can be overcome by inhibition of 
CPT1A-mediated FAO. Functional studies show that both fatty acids and ketone bodies are used 
to a greater extent when compensating for decreased levels of glucose. We also identify that FAs 
in particular participate as metabolic substrates to support a number of critical metabolic pathways 
throughout the GBM metabolome, as opposed to functioning solely in the production of ATP. This 
study suggests that GBM metabolism is more adaptable than previously thought whereby they 
utilize pathways other than aerobic glycolysis to promote cell viability and proliferation. 
 
Results 
Fatty acid and ketone oxidation in U87 
In order to determine whether GBMs are capable of oxidizing fatty acids we first examined 
expression levels of CPT1, the rate-limiting enzyme required for FAO. Analysis of the TCGA 
dataset from primary GBM tumors reveals that of the three CPT1 isoforms found in humans, 
CPT1A and CPT1C are most highly expressed in GBM (Figure 16A). Inhibition of these enzymes 
with the CPT1-specific inhibitor etomoxir (ETOM) significantly diminished U87 cell growth (cell 
number) in vitro (Figure 16B). 
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Figure 16. U87 GBM cells oxidize fatty acids and ketone bodies to support 
growth. A. Relative mRNA expression of the 3 CPT1 isoforms in GBM based on analysis of the 
TCGA dataset from primary human GBM tumors. B. Quantification of the effects of 100 uM 
ETOM treatment on U87 cell growth. Culture growth was assessed following a 7 day treatment 
with ETOM administered twice per week. C-D. Effects of FA and ketone supplementation under 
variable concentrations of glucose following a 7 day growth period in U87 cells. Error bars denote 
+/- SD. (* = p<0.05)  
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Because gliomasphere media used for in vitro studies contains high levels of glucose (25 
mM) not found naturally in the human brain or in brain tumors, a glucose-limiting assay was 
performed to assess both fatty acid and ketone body utilization under more physiologically relevant 
glucose levels, with 2.5 mM glucose representing extracellular levels commonly found in the brain 
and 1 mM glucose serving as a low glucose condition to more closely mimic levels found in tissue 
that do not have adequate access to vascular supplies of glucose171. Palmitic acid supplementation 
(25-100 mM) partially rescued U87 cell growth under 2.5 mM low glucose conditions (Figure 
16C), whereas ketone supplementation with 2.5-5 mM 3-hydroxybutyrate (3-OHB) promoted cell 
growth in both 2.5 mM and 1 mM glucose (Figure 16D). Neither FA nor ketone supplementation 
had growth-promoting effects under non-physiological conditions of high glucose (25 mM).  
To further determine how and where FAs are utilized within U87 cells, untreated CNTL 
cells, cells treated with ETOM, and cells with CPT1A knockdown were subjected to LC-MS 
metabolomic analysis using fully-labeled 13C palmitic acid in physiological glucose conditions 
(2.5 mM). Analyzing fractional contribution (or the percent of labeled carbons for each metabolite) 
within these samples revealed labeling throughout the TCA cycle as well as in the ubiquitously 
important currency metabolite ATP. Treatment with ETOM or CPT1A knockdown dramatically 
diminished this labeling (Figure 17A). Similar effects were observed when analyzing the relative 
amounts of these metabolites, wherein ETOM treatment and CPT1A knockdown significantly 
decrease levels of TCA-associated metabolites, acetyl-CoA, and ATP (Figure 17B). Taken 
together these data confirm FAO utilization while also suggesting that of the 3 CPT1 isoforms, 
CPT1A appeared to be the primary isoform regulating this process in GBM.  
  
 63 
 
Figure 17. U87 GBM cells oxidize fatty acids to generate TCA cycle 
intermediates and currency metabolites. A-B. Effects of ETOM and CPT1A knockdown 
in U87 cells on fractional contribution (the percent of labeled carbons for each metabolite) and 
relative amounts of relevant TCA cycle intermediates and currency metabolites using 13C-
palmitate LC-MS analysis. Glucose concentration = 2.5 mM) Error bars = +/- SD. (*=p<0.05, 
**=p<0.01, ***=p<0.001). 
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CPT1A knockdown and the ketogenic diet 
Based on these initial results and previous studies172, 173 that have indicated that many brain 
tumors may lack the ability to oxidize ketones as an energy substrate, we sought to determine if 
inhibiting FAO while concurrently implementing a ketogenic diet using an orthotopic xenograft 
model in mice might serve as an effective therapeutic strategy. It is thought that this strategy would 
reduce the availability of glucose as an energy substrate and make the GBM cells more vulnerable 
to cell death (starvation) by also inhibiting FAO as an alternative energy source. Because 
expression data indicated that CPT1A is most highly expressed in GBM, lentiviral shRNAs were 
used to knockdown CPT1A in U87 cells expressing firefly luciferase-GFP (Fluc-GFP). While this 
did not result in complete knockdown, the degree of knockdown was sufficient to significantly 
inhibit in vitro cell growth by ~40% to levels near what was observed with ETOM alone (Figure 
18A), once again suggesting that CPT1A is the primary isoform regulating FAO in these cells. 
This also demonstrates the importance of endogenous fatty acid oxidation to the maintenance of 
normal in vitro cell growth in these GBM cells despite U87s having a PTEN mutation which 
increases PI3K/AKT/mTOR signaling, which has been previously thought to inhibit FAO in GBM.  
To assess these results in vivo as well as to determine the effectiveness of the KD on tumor growth, 
U87 cells (shCNTL and shCPT1A) were injected into the striatum of adult NSG mice. On day 4, 
half of each group was switched to a calorie-unrestricted KD followed by weekly bioluminescent 
imaging with luciferin as shown in Figure 18B. At 21 days post-injection, animal weights, blood 
glucose levels, and blood ketone levels were evaluated. Both of the ketogenic diet cohorts 
(shCNTL and shCPT1A) exhibited decreased total body weight, decreased blood glucose levels, 
and increased blood 3-hydroxybutyrate levels, confirming ketosis was achieved in these animals 
(Figure 18C-E).  
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Figure 18. The unrestricted ketogenic diet causes ketosis in mice transplanted 
with U87 cells. A. Western blot of fluc-GFP expressing U87 cells infected with either shCNTL 
or shCPT1A lentivirus. Quantification of 7 day growth in U87 shCNTL and U87 shCPT1A (Error 
bars = +/- SD). B. Basic schematic of the experimental design for the U87 shCPT1A ketogenic 
diet xenotransplant experiment. Cells were injected on Day 0. Mice were kept on standard chow 
for 4 days to allow appropriate recovery, after which half of each group was placed on the 
ketogenic diet. On Day 8, weekly bioluminescent imaging was initiated. On Day 21 mouse weight, 
blood glucose and ketone measurements were taken. C-E. Assessment of mouse weight, blood 
glucose, and blood ketone levels on Day 21. Error bars denote +/- SEM. 
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Contrary to our initial hypothesis, analysis from weekly bioluminescent imaging shows 
that the shCNTL cohort receiving the KD had the greatest percent increase in tumor size, but that 
this increased growth was abrogated by CPT1A knockdown (Figure 19A). A similar experiment 
using a CPT1A CRISPR/Cas9 system corroborated the finding that the KD promoted U87 tumor 
growth, but that this could be overcome by CPT1A-mediated FAO inhibition (Figure 20). These 
findings were mirrored by analysis of mouse survival. The poorest survival was observed in the 
shCNTL group receiving the KD and the greatest in the shCPT1A group receiving standard chow. 
(Figure 19B). Immunohistochemisty of sectioned post-mortem tissue confirmed that CPT1A 
knockdown was maintained throughout the length of the experiment (Figure 19C). Knockdown of 
CPT1C in U87 had inhibitory growth effects in vitro, albeit not to the degree of CPT1A 
knockdown, but there were no observable differences in tumor growth in vivo when compared to 
shCNTL cells. The findings using our model, while surprising, may indicate a previously unknown 
ability of GBM cells to thrive under ketosis while also highlighting an important role of CPT1A-
mediated FAO in regulating this process.  
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Figure 19. The ketogenic diet increases U87 tumor growth but this is overcome 
by CPT1A knockdown. A. Evaluation of tumor growth based on percent increase in total 
flux [p/s] from Week 1 measurements. Tumor growth was quantified for each individual animal 
and then averaged by group (Error Bars = +/- SD). B. Assessment of mouse survival over the 
course of the experiment. Survival was tracked for individual animals until either death or 
progression to a moribund state. C. Immunohistochemistry of CPT1A in sectioned tissue following 
brain perfusion. Tissue was sectioned at a thickness of 20 uM.  
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Figure 20. CRISPR/Cas9 model validates the effects of the ketogenic diet and 
shCPT1A knockdown on U87 tumor growth. A. Western blot showing expression of 
CPT1A relative to beta-actin for cells infected with either CNTL or CPT1A CRISPR 
guideRNA/Cas9. B. Evaluation of tumor growth based on percent increase in total flux [p/s] from 
Week 1 measurements. Tumor growth was quantified for each individual animal and then averaged 
by group (Error Bars = +/- SD). The experimental design for these transplants can be found in 
Figure 18B. 
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Primary GBM gliomasphere cultures 
While U87 cells are a reasonable model to test biochemical hypotheses in GBM, the cells 
bear significant differences from primary GBM cells.  In order to confirm the potential importance 
of fatty acid oxidation in GBM we examined the potential of primary gliomasphere cultures to 
oxidize FAs and ketone bodies to support growth and cell survival. Analysis of our gliomasphere 
microarray dataset124 was performed to determine whether our primary cultures express the CPT1 
isoforms, similar to that of tumors (Figure 16A). This analysis revealed once again that CPT1A 
and CPT1C were more highly expressed than CPT1B (Figure 21A). Protein expression of these 
isoforms was confirmed using Western blot and immunocytochemistry. Respiration using 
palmitoyl-CoA as a substrate in primary GBM lines confirmed that CPT1-mediated FAO occurred 
in these cells (Figure 21B).  
While other studies have utilized ETOM up to millimolar concentrations, more recent 
research indicates that 3 µM ETOM is sufficient to fully inhibit CPT1 activity in macrophages, 
with excessive concentrations resulting in off-target effects80. The concentration of ETOM 
required to fully saturate CPT1 activity in GBM has not yet been established, however, so we 
sought to address this issue by analyzing differences between 3 µM and 100 µM ETOM on basal 
oxygen consumption rates. The higher dose slightly decreased oxygen consumption in two of the 
cell lines, suggesting a potential off-target effect of 100 µM ETOM (Figure 21C). However, further 
analysis using palmitic acid and ETOM clearly demonstrated that GBM cells are able to actively 
oxidize both endogenous and exogenous FAs (Figure 21D). We also assessed the ability of a 
primary GBM (HK157) to utilize exogenously supplied FA and 3-OHB as an energy substrate to 
support cellular growth in both physiological and high glucose conditions (Figures 21E-F). Similar 
to what was observed in U87 cells, both exogenously supplemented FA and 3-OHB had growth-
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promoting effects under lower and more physiologically relevant glucose levels (2.5 mM), 
demonstrating the ability of the primary GBM to utilize alternative substrates. 
 
Figure 21. Primary GBM cells oxidize fatty acids and ketone bodies to support 
growth. A. Relative CPT1 isoform expression (mRNA) based on our microarray dataset from 67 
primary gliomasphere cell lines and relative protein expression (Western blot) of CPT1 isoforms 
across a panel of gliomasphere cell lines. B. Western blot showing expression of CPT1A and 
CPT1C relative to beta-actin for the 4 lines used for Seahorse analysis. Quantification of maximal 
CPT1-driven respiration in lysed cells treated with palmitoyl-CoA using Seahorse analysis. C. 
Quantification of basal respiration (OCR) in cell lines incubated with either 0 uM, 3 uM, or 100 
uM ETOM to test for potential off-target effects using Seahorse. D. Seahorse analysis to assess 
both endogenous and exogenous FAO. Endogenous oxidation was measured by adding 100 uM 
ETOM (indicated by arrow). Exogenous oxidation was measured by adding palmitic acid (FA 
arrow) followed by 100uM ETOM (ETOM arrow). E-F. Effects of FA and ketone supplementation 
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in a primary GBM cell line (HK157) under variable concentrations of glucose following a 7 day 
growth period. Error bars denote +/- SD.     
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To further assess inhibition of endogenous FAO on GBM cell growth and survival we 
tested the effects of ETOM in a panel of primary GBM cultures. These experiments were initially 
done under high glucose, non-FA supplemented conditions. A 7-day treatment with ETOM 
resulted in diminished overall culture growth for all gliomasphere lines tested (Figure 22A). This 
analysis yielded no significant differences with regard to IDH1 mutant status, PTEN deficiency, 
EGFR amplification, or the presence of the EGFRviii mutation (data not shown). Interestingly, 
ETOM treatment did not inhibit the growth of cultured human fetal neurospheres or SVZ-derived 
mouse neurospheres. This may indicate that FAO is GBM-specific, irrespective of mutational 
status, and less important to healthy tissue making it a potentially attractive therapeutic target. 
Following a 4-day treatment with ETOM we found a significant decrease in actively dividing cells 
as assessed using bromodeoxyuridine (Brdu) incorporation (Figure 22B), demonstrating the 
importance of endogenous FAO to the maintenance of cell proliferation even in GBMs (HK301) 
with a mutation that enhances AKT pathway signaling. In addition to these effects on proliferation 
we also observed an increase in cell death as measured by annexin V/propidium iodide staining 
(FACS) following treatment with ETOM (Figure 22C). Analysis of ETOM treatment on 
intracellular reactive oxygen species (ROS) levels revealed no change in total intracellular ROS. 
Treatment did increase mitochondrial superoxide levels across all lines tested (Figure 22D) 
suggesting that etomoxir, which binds to CPT1 on the outer mitochondrial membrane, specifically 
alters ongoing FA mitochondrial oxidative metabolism. A 7-day growth assay in a number of 
primary GBM lines of varying mutational status was performed in 2.5 mM glucose, representative 
of physiological levels. This showed a slight increase in sensitivity to ETOM inhibition of 
endogenous FAO than what was observed in 25 mM glucose (Figure 22E). We also assessed the 
ability of the primary GBMs to utilize exogenously supplied FA and 3-OHB as an energy substrate 
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to support cellular growth at 2.5 mM glucose (Figure 22E). Our results indicate that there is 
increased variability in the ability of the cells to promote cell growth from what was observed in 
the U87 glioma cell line (Figure 16C-D), likely representing a heterogeneity among GBMs to 
utilize these alternative substrates in place of glucose. Taken together, these data support our 
hypothesis that FAO is a significant contributor to overall GBM metabolism and growth, which is 
not prevented by PI3K/AKT/mTOR pathway-promoting mutations in our lines as has been 
observed in previous studies on GBM glucose dependency and fatty acid utilization174, 175, 176. 
 
 
Figure 22  
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Figure 22. Etomoxir inhibits primary GBM cell proliferation and promotes cell 
death while increasing mitochondrial ROS levels. A. Quantification of the effects of 7 
day 100 uM ETOM treatment (administered twice per week) across a panel of primary GBM cell 
lines and two non-GBM controls (adult mouse-derived neurospheres and human fetal-derived 
neurospheres). Cell growth was calculated based on actual cell counts. Error bars = +/- SEM. 
Cultures that are EGFR amplified, EGFR ampified + EGFRviii mutant, IDH1 mutant, and PTEN 
deficient are indicated. B. Assessment of actively dividing cells by Brdu immunocytochemisty in 
two primary GBM lines grown for 4 days in the presence of 100 uM ETOM. C. FACS analysis of 
cell death using dual Annexin V/PI staining in HK157 cells following 4 day treatment with 100 
uM ETOM. D. Evaluation of total ROS levels (CellROX Deep Red) and mitochondrial superoxide 
levels (with MitoSOX Red Reagent) by flow cytometry. Left: histogram showing actual 
fluorescent readout of one cell line. Right: Graph quantifying mean fluorescent intensities for each 
line. E. 7 day growth assessment (cell counts) with 100 uM ETOM, 50 mM palmitate (FA), and 
1.25 mM 3-OHB in 2.5 mM glucose. All other experiments were performed in 25 mM glucose. 
Error bars = +/- SD.  
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LC-MS with fully-labeled palmitic acid 
We utilized LC-MS analysis with fully-labeled 13C palmitic acid to characterize the 
contribution of FAO to the metabolome of primary GBM cells. Fractional contribution studies 
revealed that ETOM treatment caused widespread changes in carbon labeling across the 
metabolome (Figure 23A).  Importantly, ETOM resulted in diminished labeling of acetyl-CoA, the 
end product of FAO, along with an increase in the amount of labeled palmitate within the cell 
(Figure 23B). Both results confirmed that labeled FAs were taken up and oxidized within the cell. 
In addition to acetyl-CoA, ETOM treatment also resulted in diminished labeling within the TCA 
cycle and among metabolites that commonly feed into the TCA cycle such as glutamine, 
glutamate, and lactate (Figure 23B). Analysis of the relative amounts of metabolites with ETOM 
treatment did not result in changes to overall acetyl-CoA or palmitate levels. However, ETOM 
treatment did result in lower relative levels of TCA-associated metabolites which include alpha-
ketoglutarate, citrate, fumarate, glutamine, and glutamate (Figure 23C). A full list of significantly 
altered metabolites resulting from FAO inhibition with ETOM (Table 1) demonstrates that GBM 
cells utilize FAO to support a number of critical metabolic pathways throughout the GBM 
metabolome.  
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Figure 23. GBM cells oxidize FAs to generate acetyl-CoA for use within the 
TCA cycle. A-B. LC-MS analysis of 13C-palmitic acid fractional contribution following 
treatment with 100 uM ETOM. A. Heat map showing effects of ETOM on fractional contribution 
across metabolites. B. Quantification of the effects of ETOM on intracellular carbon labeling of 
acetyl-CoA, palmitic acid, and other relevant metabolites associated with the TCA cycle. C. 
Effects of ETOM on relative amounts of relevant metabolites as in B. ETOM concentration used: 
100 uM. Error bars = +/- SD. (* = p<0.05, ** = p<0.01, *** = p<0.001). 
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Table 1. GBM cells utilize fatty acids to support other metabolic pathways in 
addition to the TCA cycle. List of all metabolites significantly altered by ETOM (100 uM) 
treatment with regard to fractional contribution and relative amounts of labeled 13C-palmitic acid 
using LC-MS analysis. Cell line: HK157. (p<0.05 for all metabolites listed). 
  
TCA Cycle Pentose Phosphate Nucleotide Metabolism
Amino Acid
Metabolism
Fatty Acid/Lipid 
Metabolism Currency Other
Aconitate SAM 5M-adenosine Asn Ac-carnitine Acetyl-CoA GlcN-6P*
Cit ATP Asp CDP ATP HMG-CoA
Fum C Pro CDP-EtA GSH
Lac CMP P-Ser Palmitate* GSSG
Mal CTP
Succ Cytosine
Hypoxanthine
Gln Orotidine
Glu UDP
UDP-Glc
UDP-GlcNAc
UMP
UTP
Significantly different Metabolites (p<0.05): (* indicates increased levels with ETOM)
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l C
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a-KG Cystathionine ATP Ala Ac-carnitine ATP GlcN-6P
Cit G6P-F6P dATP Pro P-Choline Creatine 4-OH-PheLac
Fum IMP* CDP Ser P-EtA NADH Inositol
Aconitate R5P* CTP Thr AMP/ATP Ratio* Vit-C
GTP Citrulline
Gln UTP 2-Methylpropanoyl-CoA
Glu Orotidine
C*
Cytosine*
G*
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Fatty acid oxidation in IDH1 mutant GBM  
 Recent studies, including one from our own group1, have demonstrated that GBMs 
harboring an isocitrate dehydrogenase 1 (IDH1) mutation represent a metabolically distinct subset 
of glioma. Because of this, we sought to identify potential differences in FAO utilization between 
our IDH1 mutant and IDH WT gliomasphere cultures. Analysis of microarray data from 67 
gliomasphere lines, 7 of which are IDH1 mutant, revealed elevated mRNA expression of CPT1A 
in IDH1 mutant lines (Figure 24A) compared to IDH wildtype cultures. Western blot analysis 
confirmed elevated CPT1A protein expression (Figure 24B). Similar to IDH WT cells, LC-MS 
analysis with fully-labeled palmitic acid in an IDH1 mutant cell line showed diminished labeling 
of acetyl-CoA and several TCA-associated metabolites when treated with ETOM (Figure 24C). 
Interestingly, 2-hydroxyglutarate (2-HG), a proposed oncometabolite and the resulting product of 
the IDH1 mutant enzyme itself, was among the most heavily labeled metabolites in this particular 
IDH1 mutant line. Treatment with ETOM significantly diminished both the fractional contribution 
and relative amount of intracellular 2-HG, suggesting that FAO may serve as a major contributor 
to 2-HG production in IDH1 mutant GBMs (Figure 24C-D). FAO inhibition with ETOM in IDH1 
mutant cells did not result in a decrease in the relative amounts of TCA cycle intermediates as was 
observed in IDH WT cells (Figure 24D, Figure 25), perhaps indicating a greater reliance on FAO 
to feed the TCA cycle in IDH WT GBM. Analysis of the full list of significantly different 
metabolites revealed fewer overall metabolites altered by ETOM treatment in IDH1 mutant cells 
(Table 2). These data confirm FAO utilization in both IDH1 mutant and wildtype cells while 
highlighting several potentially important metabolic differences between the two. Further 
investigation with a greater number of IDH mutant and wildtype lines will be needed to fully 
elucidate these differences.  
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Figure 24. IDH1 mutant GBM cells express higher levels of CPT1A and utilize 
fatty acids to produce 2-HG. A. mRNA expression of CPT1 isoforms in IDH1 mutant and 
wildtype primary GBM cultures based on analysis of microarray data as in Figure 21A. B. Protein 
expression (Western blot) of CPT1A and CPT1C across a panel of IDH wildtype and IDH1 mutant 
lines. C-D. Analysis of the effects of ETOM (100 uM) in an IDH1 mutant cell line on fractional 
contribution and relative amounts of relevant metabolites using 13C-palmitic acid LC-MS. Error 
bars = +/- SD. (* = p<0.05, ** = p<0.01, *** = p<0.001).   
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Figure 25. CPT1 inhibition with ETOM does not alter relative amounts of TCA 
metabolites in IDH1 mutant cells. Analysis of the effects of 100 uM ETOM on relative 
amounts of TCA metabolites in an IDH1 mutant line using 13C-palmitic acid (LC-MS). Error bars 
= +/- SD. p-value = >0.5 (N.S.) for all metabolites shown. 
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Table 2. IDH1 mutant GBM cells may utilize FAs differently than IDH 
wildtype. Identical analysis to that of Table 1 showing all metabolites that are significantly 
altered by ETOM (100 uM) treatment in an IDH1 mutant line (HK252). The metabolites listed in 
Table 1 are from analysis of an IDH wildtype line. (p<0.05 for all metabolites listed). 
 
 
  
Significantly different Metabolites (p<0.05): (* indicates increased levels with ETOM)
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TCA Cycle Nucleotide Metabolism Amino Acid Metabolism Fatty Acid/Lipid Metabolism Currency Other
Aconitate A Asn Ac-carnitine Acetyl-CoA GlcNAc-6P
Cit Adenine Asp CDP ATP
Mal ATP Arg* CDP-EtA GSH
Succ C Homocysteine GSSG
2-HG CMP Pro
Gln CTP
Glu Cytosine
dG
Inosine
Orotidine
UDP
UDP-Glc
UDP-GlcNAc
UMP
UTP
2-HG Adenine* 2-Methylpropanoyl-CoA Acetyl-CoA F16BP
Glu dA* Gly Creatine G6P-F6P
GMP NADH GlcN-6P
Inosine* GlcNAc-6P
Orotate* Pantothenate
Sorbitol
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Discussion 
Identifying metabolic vulnerabilities in cancer for use in targeted therapies has been a topic 
of interest for decades. While glucose metabolism has drawn the most attention in the scientific 
community, the ability of brain tumor cells to use other substrates for cellular maintenance and to 
meet bioenergetic demands has become increasingly evident23, 159, 177, 97. In the current study we 
sought to investigate the ability of brain tumors to oxidize two such metabolic substrates to support 
growth: fatty acids and ketone bodies. We demonstrated that GBM cells are able to oxidize both 
FAs and ketones, particularly under physiologically relevant glucose conditions. We also found 
that the ketogenic diet (KD) administered ad libitum was sufficient to induce ketosis and, contrary 
to expectations, this diet resulted in long-term increases in GBM tumor growth using an animal 
orthotopic xenograft model. This increased tumor growth could be abrogated, however, by 
inhibition of FAO through CPT1A knockdown. A more in-depth in vitro assessment using primary 
GBM cultures demonstrated CPT1 functionality in these cells. Inhibition of CPT1-mediated FAO 
either through CPT1 knockdown using lentiviral shRNAs or pharmacologically with the CPT1-
specific inhibitor etomoxir resulted in decreased proliferation, increased cell death, and elevated 
ROS production. LC-MS tracing experiments with fully-labeled FAs showed significant FA 
utilization within the TCA cycle that extended throughout the GBM metabolome, highlighting a 
potential reliance on FAO to support GBM’s aggressive phenotype.  
 Several lines of evidence exist for the use of a KD to treat brain tumors. The first lies with 
the innate ability of the human body to efficiently adapt to ketosis178. For example, the KD has 
been successfully implemented to treat certain diseases such as refractory pediatric epilepsy with 
no clear sustained adverse health effects179, 180, 181. Additionally, several previous studies have 
indicated that many brain tumors may lack the ability to oxidize ketones due to decreased 
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expression of several mitochondrial genes required to do so172, 173, although there is also evidence 
suggesting gliomas oxidize ketone bodies at comparable levels to the brain when exposed to a 
KD95. Our study shows that as glucose levels are diminished, GBM cells can adapt by at least 
partially shifting their metabolism to accommodate ketone body oxidation. Prior animal studies 
investigating the therapeutic potential of the KD have yielded mixed results, usually depending on 
the manner of administration and ability to achieve ketosis82, 96, 182, 183. One study using U87 cells 
in a mouse tumor model found that an ad libitum KD resulted in increased blood ketone levels 
without affecting blood glucose or tumor growth96. Only with a calorie-restricted KD were glucose 
levels and tumor growth diminished. This is consistent with other studies demonstrating anti-tumor 
effects of calorie restriction irrespective of the KD97, 98, 99.  Here we report that the ad libitum KD, 
albeit of a slightly different formulation and longer period of administration, significantly elevated 
blood ketone levels, decreased blood glucose, but resulted in increased tumor growth. While it is 
possible that the KD can have some therapeutic utility depending on its implementation, our data 
suggest that clinical trials investigating such treatments need to proceed with a great deal of 
caution163, 184, 185, 186.     
In addition to ketone body metabolism, this study also focused on the ability of GBMs to 
oxidize FAs. Similar to other previous studies, we report that GBM cells express the necessary 
enzymes involved in FAO, utilize FAs to support overall metabolism, and that inhibition of this 
process has anti-proliferative effects79, 78, 77. Our results also suggest that the ability to oxidize FAs 
may be intrinsic to GBM and is not directly counteracted by EGFR amplification, constitutive 
activation (EGFRviii mutation), or PTEN mutations, as U87 cells themselves, are deficient in 
PTEN, as are a number of our primary gliomasphere lines. Activation of the PI3K/Akt/mTOR 
pathway have been implicated in glucose addiction, a dependence on aerobic glycolysis and 
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inability to efficiently utilize alternative substrates that leaves malignant cells particularly 
vulnerable to glucose starvation105, 187, and can produce metabolic shifts towards FA synthesis165. 
However, our current study suggests that under physiologically relevant glucose conditions (2.5 
mM), FAs play a central role in the overall GBM metabolome regardless of mutational status. Our 
findings of a mutation-independent use of FAO in GBMs may be due to methodological 
differences with previous studies such as our use of physiological glucose levels or lower ETOM 
concentrations to limit off-target effects. Furthermore, our surprising in vivo findings that show an 
increase in U87 tumor growth with a ketogenic diet support our in vitro findings that AKT-
enhancing mutations don’t make GBMs “glucose addicted” under physiological conditions. The 
ketogenic diet limits the availability of glucose to the tumor in vivo, so the enhanced tumor growth 
we observed must have been supported by the use of alternative energy substrates despite U87s 
having PTEN mutations.  
FAO by these tumors may at first glance seem counterintuitive since the brain receives an 
ample supply of glucose, the most highly utilized substrate in GBM. ATP generation by FAO also 
demands more oxygen, is a slower overall process, and generates more superoxide than 
glycolysis71. While the idea of simultaneous FA synthesis and oxidation seems counterproductive, 
studies such as this make it increasingly clear that the ability to oxidize FAs make malignant cells 
more resilient and adaptable to conditions of metabolic stress, which highly proliferative and 
migratory cells like GBMs experience during tumor formation. FAs represent a readily available 
and easily stored substrate that can be utilized to support both bioenergetic demands and as a raw 
material for the production of other cellular components. In malignant glioma tumors, lipid levels 
have been reported to be higher compared with normal brain tissues188, 189, 190. Gliomas can both 
produce free fatty acids and lipid stores endogenously via de novo synthesis from excess glucose 
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and via uptake of exogenously produced free fatty acids from blood. Our experiments suggest that 
both endogenous and exogenous sources of fatty acids can be used as an energy substrate to support 
cell growth in GBMs. Perhaps the most notable aspect of FAO is that it results in the production 
of acetyl-CoA, an important metabolite that regulates a number of cellular processes including the 
TCA cycle. Recent evidence demonstrates that much of the acetyl-CoA produced by malignant 
gliomas is derived from sources other than glucose191, highlighting FAO as a potentially critical 
contributor to overall brain tumor metabolism. Our 13C-labeled FA tracing experiments support 
this finding and demonstrate that in addition to feeding into the TCA cycle, FAO contributes 
extensively throughout the GBM metabolome. 
While investigating FA metabolism in GBM as a whole, we also sought to characterize 
potential differences in FAO utilization between IDH1 mutant and wildtype GBM cells. Recent 
evidence suggests that GBMs harboring IDH mutations represent a distinct subclass of glioma141. 
Our group previously demonstrated that IDH1 mutant gliomaspheres are metabolically 
distinguishable from their WT counterparts based on expression profiles, glucose consumption, 
and nucleotide synthesis utilization1. The results of this study suggest further metabolic differences 
in IDH mutant GBM cells with regard to FAO. Analysis of CPT1-isoform expression revealed 
increased expression of CPT1A in IDH1 mutant cultures relative to IDH wildtype cells. LC-MS 
tracing experiments with 13C-palmitic acid revealed extensive FA utilization throughout the 
metabolomes of both IDH mutant and WT cells. However, the effects of FAO inhibition with 
ETOM was more pronounced within the TCA cycle of IDH WT cells. Importantly, 2-HG was 
among the most heavily labeled metabolites in IDH mutant cells. Treatment with ETOM 
significantly decreased both the fractional contribution and relative amount of 2-HG, indicating 
FAs may serve as a vital component for the production of this proposed oncometabolite. While 
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these effects were only tested in a single IDH1 mutant cell line, and thus require further 
investigation, these results suggest FAO represents an additional mechanism contributing to the 
unique metabolic phenotype of IDH mutant gliomas.  
In this study we also report that inhibition of CPT1A-mediated FAO results in decreased 
tumor growth and improved survival using a murine orthotopic xenograft model. Of note, we 
identified that CPT1A knockdown was sufficient to nullify the observed increases in tumor growth 
resulting from administration of a ketogenic diet. While the KD leads to increased production of 
ketone bodies such as beta-hydroxybutyrate, it also results in increased FA availability with the 
potential to be taken up and utilized by the tumor192, 193. Our results suggest that GBMs are able to 
compensate for decreased glucose availability by shifting their metabolism toward FAO. This 
hypothesis is supported by a study in which FAO inhibition through administration of etomoxir 
prolonged survival in a syngeneic mouse model of malignant glioma78. Similarly, our orthotopic 
xenograft experiments resulted in prolonged survival for those cohorts bearing tumors with 
CPT1A knockdown, irrespective of the ketogenic diet. These results provide strong evidence that 
FAO is a significant pathway in GBM and may serve as a valuable therapeutic target either alone 
or in combination with other currently investigated treatments.  
Although our findings emphasize the complex and highly adaptable nature of brain tumor 
metabolism, important aspects of these studies require further investigation. In vivo tumor studies 
were conducted in immunosuppressed mice using the U87 malignant glioma cell line. This cell 
line was used because of its experimental consistency, similar FAO profile to primary GBM lines, 
and its ability to establish tumors quickly. The speed of tumor formation was important, not simply 
for convenience, but it allowed us to take into account concerns regarding significant weight loss 
and the overall health of animals receiving a long-term ketogenic diet. Utilizing multiple primary 
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cell lines or adapting an in vivo model in immunocompetent animals to better mimic brain tumor 
physiology and the tumor microenvironment could further our understanding of these intricate 
metabolic processes. The preponderance of evidence reported in this study support the conclusion 
that GBMs oxidize FAs. Inhibition of FAO with ETOM resulted in overall deficits in cellular 
growth and FA-mediated mitochondrial respiration. Meanwhile, FA supplementation under 
physiologically relevant glucose concentrations demonstrated inverse effects to that of ETOM. 
Our LC-MS studies also clearly show that FAs are taken up, oxidized, and utilized throughout the 
GBM metabolome. Finally, many of the effects of FAO inhibition achieved with ETOM were 
validated using multiple methods of CPT1A knockdown. The fact that etomoxir has been shown 
to exhibit off-target effects in certain cells at high doses cannot be overlooked, however. 
Developing more potent and specific FAO inhibitors, perhaps even for individual CPT1 isoforms, 
could prove essential for targeting brain tumors in patients. Due to the grim prognosis associated 
with glioma and the currently inadequate treatment options available, this study highlights several 
important aspects of brain tumor metabolism that have direct application to improving current 
standard of care therapy. 
 
Methods 
Collection and Maintenance of In Vitro Cultures: 
Tumor samples were collected under institutional review board-approved protocols and 
graded by neuropathologists. Primary gliomasphere cultures were prepared as follows. 
Immediately after receiving resected tissue, samples were digested with papain and acellular debris 
was removed. Those cells which remained were incubated in gliomasphere defined media 
containing DMEM/F12 supplemented with B27, heparin, EGF, bFGF, and penicillin/streptomycin 
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until sphere formation was achieved. Gliomasphere stocks were frozen down at approximately 
passage 5 to maintain cells at low passage throughout the study. All cell lines used in this study, 
including U87, were continuously grown in serum-free gliomasphere media. 
 
Expression Analysis: 
Relevant expression, mutational status (such as EGFR and IDH1), and patient 
characteristics for the majority of cell lines used in this study have been previously reported124,1. 
The following cultures are known to be PTEN deficient (U87, HK217, HK229, HK296, HK301) 
but there may be other cultures that are PTEN mutated/deleted as well. Also of note, while BT142 
is IDH1 mutant (R132H), it does not produce 2-HG. HK211 is both IDH1 (R132H) and EGFRviii 
mutant. Known status of EGFR, PTEN, and IDH1 are indicated in Figure 22A for primary GBM 
cultures. Analysis of CPT1-isoform expression is based on the microarray dataset (GSE98995) 
previously described by Laks et al. 2016 and available in the Gene Expression Omnibus (GEO) 
repository. 
 
Variable Glucose Media and Substrate Supplementation: 
 All media described contain B27, heparin, EGF, bFGF, and penicillin/streptomycin. For 
25 mM glucose the base media used is Neurobasal-A Medium ([-] Glutamine) (Gibco #10888-
022) supplemented with GlutaMax Supplement (Gibco #35050061). 2.5 mM and 1 mM glucose 
media was made by combining the Neurobasal-A Medium ([-] Glutamine) above with Neurobasal-
A Medium ([-] D-glucose, [-] Sodium Pyruvate) (Gibco #A24775-01) to achieve the desired 
glucose concentration. Glutamax Supplement and sodium pyruvate (Gibco #11360-070) were then 
added to reach a final concentration of 1X. Palmitic acid was purchased from Sigma-Aldrich 
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(#P0500) and conjugated with fatty acid free, low endotoxin bovine serum albumin (BSA, Sigma 
Aldrich, #A1595). Carnitine (Sigma Aldrich, #C0283) was included in fatty acid-supplemented 
conditions. 3-hydroxybutyrate (3-OHB) was also purchased from Sigma (#166898).  
 
shRNA and CRISPR/Cas9 Lentiviral Knockdown: 
Plasmids with shCPT1A (RHS4531-EG1374 glycerol set), shCPT1-C (RHS4531-
EG126129 glycerol set), and the non-silencing shCNTL (RHS4346) cloned into pGIPZ expression 
vectors were purchased from Dharmacon. The firefly luciferase-GFP virus Fluc-GFP (backbone= 
pRRL-sinCMV-iresGFP) was produced by UCLA Vectorcore and supported by Molecular 
Technologies Core (IMTC) CURE/P30 DK41301-26. These plasmids were transfected into 293T 
cells along with 1st generation viral DR8.74 package and VSV-g envelope for production of 
lentivirus. For CRISPR experiments the following plasmids were used: CPT1A-validated CRISPR 
guideRNA (Edigene SG00441287A), LentiCas9-EGFP (Addgene 63592), and pgRNA-
humanized plasmid, (Addgene 44248). Each plasmid was used to generate three separate 
lentiviruses as described above. For CPT1A-CRISPR knockdown experiments cells were then 
infected sequentially: first with either the CPT1A guideRNA or pgRNA-humanized (CNTL) virus, 
and then with the LentiCas9-EGFP virus. Cells expressing both fluorophores for the guideRNA 
and Cas9 were selected for by fluorescence. Those selected cells were then plated at clonal density 
and expanded to achieve a more uniform population expressing both the guideRNA and Cas9 
vectors. 
 
U87 In Vivo Orthotopic Xenotransplants: 
 90 
All animal experimentation was performed with institutional approval following NIH 
guidelines using adult NSG mice. Intracranial xenotransplants were performed similarly to 
previous descriptions with minor changes194.  
-CPT1A /Ketogenic Diet: 
One hundred thousand U87 cells expressing firefly luciferase-GFP (Fluc-GFP) along with 
either shCNTL or shCPT1A plasmids were stereotactically injected into the striatum of non-obsese 
diabetic gamma null (NSG) mice under isoflurane anesthesia over 5 minutes using the following 
coordinates: 1.5 mm lateral to and -0.5 mm anterior to Bregma, and 3.0 mm below the pial surface. 
N= 10 mice per group. As shown in Figure 18B, mice were kept on standard chow for 4 days to 
allow appropriate recovery, after which half of each group was placed on the ketogenic diet 
(BioServ, S3666). On Day 8, weekly bioluminescence imaging was initiated as described below. 
On Day 21 mouse weight, blood glucose and ketone measurements were taken. Tumor growth was 
measured until each animal either died or became morbid. Mouse survival was tracked for all 
groups. This experimental design was also implemented for CPT1A CRISPR/Cas9 transplants.  
-CPT1-C Transplants: 
 Transplants for this experiment were carried out as described above with the exception that 
the ketogenic diet was not implemented and therefore only 20 total mice were used (10 per group). 
 
Bioluminescent Imaging: 
Optical imaging was performed at the Preclinical Imaging Technology Center at the Crump 
Institute for Molecular Imaging at UCLA. 100 µl of D-luciferin (GoldBio) dissolved in phosphate 
buffer saline without Ca2+ or Mg2+ (30 mg/ml) was introduced to each animal by intraperitoneal 
(IP) injection. After 7 minutes of conscious uptake, mice were anesthetized by inhalation of 2.6% 
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isoflurane in oxygen and placed in dedicated imaging chambers. The IVIS Lumina 2 imaging 
system (Caliper Life Sciences) was utilized for in vivo bioluminescent imaging. A corresponding 
photograph of the mice was taken and co-registered with the luminescent image for signal 
localization. Images were analyzed by drawing regions of interest and quantified as total flux 
(photons/second) with the Living Image software package (Perkin Elmer). 
 
Western Blot and Immunohistochemistry: 
Western blots were performed using the following antibodies: mouse anti CPT1A (abcam, 
128568), rabbit anti CPT1B (abclonal, A6796), rabbit anti CPT1C (LsBio, LS-C167010), rabbit 
and mouse anti beta-actin (Abcam). To prepare samples for immunohistochemical analysis, Mouse 
brains from U87 transplant experiments were perfused using 4% paraformaldehyde (PFA) and 
incubated overnight in PFA at 4°C for 24 hours. Tissue was washed with PBS and incubated in 
20% sucrose at 4°C for a minimum of 24 hours in preparation for sectioning on a cryostat. Sections 
(20 µM thick) were post-fixed for 15 minutes with cold 4% paraformaldehyde followed by 3x 
washes with TBS prior to performing immunohistochemistry for CPT1A. 
 
Seahorse Respirometry Methods: 
All respirometry studies were conducted in a Seahorse XFe96 Analyzer. All experiments 
were conducted at 37°C, and at pH 7.4 (intact cells) or 7.2 (permeabilized cells). On the day of the 
assay, glioblastoma cells were acutely spun onto Seahorse XF96 plates (600g for 5 min) coated 
with Cell-Tak (Corning C354240) according to manufacturer’s instructions at 4.3x104 cells/well. 
Respiratory parameters were calculated according to standard protocols195, and all rates were 
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corrected for non-mitochondrial respiration/background signal by subtracting the oxygen 
consumption rate insensitive to rotenone and antimycin A. 
-Intact Cells: 
Potential off-target effects of etomoxir in intact glioblastoma cells was assessed by 
measuring respiration in response to both 3 µM and 100 µM etomoxir80. Prior to conducting the 
assay, cell culture medium was replaced with DMEM (Sigma D5030) supplemented with 8 mM 
glucose, 2 mM pyruvate, 2 mM glutamine and 5 mM HEPES. Respiration was measured in the 
basal state as well as in response to 2 μM oligomycin, FCCP (two sequential pulses of 800 nM), 
and 0.2 μM rotenone with 1 μM antimycin A. Etomoxir (3 μM or 100 μM) was added to the assay 
medium 30 min prior to measurements. 
-Permeabilized Cells: 
The plasma membrane of cells was selectively permeabilized with recombinant, mutant 
perfringolysin O196 and experiments were conducted as previously described80. Immediately prior 
to the assay, cell culture medium was replaced with MAS buffer containing 3 nM rPFO, 40 µM 
palmitoyl CoA, 1 mM malate, 0.5 mM carnitine, and 4 mM ADP. Maximal CPT-1-driven 
respiration rates are given as the rate stimulated by 2 μM FCCP corrected for background with 0.2 
μM rotenone with 1 μM antimycin A. 
 
Acute etomoxir treatment and fatty acid and ketone supplementation: 
Dissociated cultures were plated at a density of 50k cells/ml in triplicate in gliomasphere 
defined media containing 25 mM glucose unless otherwise indicated. Cells were incubated for 24 
hours after which point 100 µM etomoxir was added to each sample and again on day 4. [(+)-
Etomoxir sodium salt hydrate, Sigma Aldrich, #E1905]. For FA and ketone supplementation, 
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4,000 cells were plated per well (96-well plates) and incubated for 24 hours after which either FAs 
or ketones were added to yield the following final concentrations of each. For FA: 25-200 µM 
palmitate (Sigma Aldrich, #P0500) bound to fatty-acid free BSA (5g/50mL in 10% PBS) (Sigma 
Aldrich, #A1595) and 500 µM carnitine (Sigma Aldrich, # C0283). For 3-OHB (Sigma Aldrich, 
#166898): final concentrations were 1.25-10 mM.  Blood plasma concentrations of these substrates 
in healthy adults range from 111-260 µM palmitate and 67 µM carnitine197, 198, 199. Cells were 
allowed to grow for the indicated period of time prior to analysis using the Dojindo Cell Counting 
Kit 8 (#CK04-20) according to manufacturer instructions. 
 
Cell growth analysis: 
Single-cell suspensions were made from bulk cultures of the U87 and primary glioma cell 
lines and counted using a Countess automated cell counter. Cells were plated at 50k cells/mL in 
6-well plates and grown as gliomaspheres in control or experimental conditions. For ETOM 
experiments, cells were treated 24 hours after initial plating and treatment was re-administered on 
Day 4. After 7 days the gliomaspheres in each well were fully dissociated and re-counted to assess 
changes in cell number during treatment. This analysis of cell number examines both cell survival 
and proliferation in response to treatment. 
 
Proliferation analysis with bromodeoxyuridine (BrdU): 
 Single cell suspensions were plated as a monolayer on laminin-coated glass coverslips 
(Sigma, L2020) in 24-well plates followed by a 4 day ETOM treatment. Two BrdU pulses were 
given 2 hours apart and cells were fixed for 15 minutes with 4% paraformaldehyde. Coverslips 
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were washed with PBS and immunocytochemistry was performed to assess the % of BrdU-positive 
cells by visual microscopic cell counts.    
 
Annexin V/PI FACS Analysis: 
Single cell samples were treated with 100uM ETOM for 4 days after which spheres were 
re-dissociated with 200 µl accumax, centrifuged, and washed 1x with PBS. Annexin 
V/propidium iodide (PI) staining was carried out according to manufacturer protocol using the 
Annexin V APC flow cytometry kit (Thermo Fisher) while including a 1µl/ml final 
concentration of PI. Samples were gently mixed and incubated with Annexin V/PI binding buffer 
and incubated for 15 minutes at room temperature protected from light. Samples were kept on ice 
and analyzed within 1 hour by flow cytometry. 
 
Reactive Oxygen Species Analysis: 
 Mitochondrial superoxide and total intracellular ROS levels were assessed according to 
manufacturer instructions following a 3 hour incubation with ETOM (100 µM) by FACS analysis. 
Mitochondrial ROS was detected using MitoSOX™ Red Mitochondrial Superoxide Indicator 
(Thermo Fisher, M36008). Total intracellular ROS was measured using CellROX™ Deep Red 
Reagent, for oxidative stress detection (Thermo Fisher, C10422). 
 
LC-MS with fully labeled 13C palmitate: 
Gliomaspheres were dissociated into single cells with Accumax™ and 200k cells were 
cultured for 48 hours in 2.5 mM glucose media in triplicate for each sample. Cells were then rinsed 
with PBS and re-plated in 2.5 mM glucose media, either unlabeled or containing 200 µM fully-
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labeled 13C-palmitic acid for an additional 48 hours. Cells were then centrifuged and rinsed with 
1ml ice-cold 150 mM ammonium acetate (pH 7.3). Centrifugation was performed again and 1ml 
of ice-cold 80% methanol was added. Cells were transferred to an Eppendorf tube, and 10 nmol 
norvaline (Sigma-Aldrich, N7502) was added to each sample. Samples were centrifuged for 5 min. 
at top speed and the supernatant was transferred into a glass vial. Samples were resuspended in 
200 µl cold 80% methanol, followed again by centrifugation, after which the supernatant was 
added to the glass vial. Samples were dried in an EZ-2Elite evaporator. The remaining pellet was 
resuspended in RIPA buffer and a Bradford assay was performed to quantify protein levels for 
sample normalization. Dried metabolites were resuspended in 50% ACN and 5 µl loaded onto a 
Luna 3 µm NH2 100 A (150 × 2.0 mm) column (Phenomenex). The chromatographic separation 
was performed on an UltiMate 3000 RSLC (Thermo Scientific) with mobile phases A (5 mM 
NH4AcO pH 9.9) and B (ACN) and a flow rate of 200 µl/min. The gradient from 15% A to 95% 
A over 18 min. was followed by 9 min. isocratic flow at 95% A and re-equilibration. Metabolite 
detection was achieved with a Thermo Scientific Q Exactive mass spectrometer run in polarity 
switching mode (+3.5 kV/− 3.5 kV). TraceFinder 4.1 (Thermo Scientific) was used to quantify the 
area under the curve for metabolites by using accurate mass measurements (< 3 ppm) and the 
retention time of purchased reference standards. Relative amounts of metabolites were calculated 
by summing up all isotopologues of a given metabolite and normalized to cell number. Correction 
for naturally occurring 13C as well as calculation of fractional contributions and clustering analyses 
were done in R. 
 
Statistical Analysis:  
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Statistical analysis was performed using either Microsoft Excel or GraphPad Prism 
software. The statistical significance of comparative samples was determined using an ANOVA 
model and two-tailed Student’s t tests where appropriate. All quantitative data and associated error 
bars represent the mean ± either the standard deviation or standard error of the mean (SEM) as 
indicated for each figure. Experiments were performed in triplicate at a minimum, with 95% 
confidence intervals and p values calculated for relevant comparison. For all figures, p values are 
represented as follows: * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Chapter 4 
 
Summary and Perspectives 
 
 
Glioblastoma (GBM) is one of the most lethal cancers and new therapeutic strategies are 
desperately needed. Although there has been considerable progress in defining the molecular 
characteristics that drive gliomagenesis, the complexities of the metabolic signaling networks 
responsible for GBM’s aggressive phenotype remain unsolved. Despite underwhelming results 
from previous attempts to establish metabolic therapies for GBM, targeting GBM metabolism 
remains an attractive approach for several reasons. While oncogenic mutations bestow added 
flexibility and adaptability, those same mutations also make GBM cells reliant on metabolic 
pathways that are not overtly essential to surrounding healthy tissue. Obtaining maximal efficacy 
with minimal side effects epitomizes the ideal outcome for any cancer regimen. Furthermore, 
because of the significant overlap between oncogenic and metabolic signaling, current oncogene-
directed therapies can be easily adapted to include additional targets based on metabolic dynamics. 
Combinatorial therapy likely represents the most effective way to overcome the interconnected, 
often redundant, signaling cascades activated during oncogenesis and metastasis. Finally, 
technological advances in drug development have made targeting metabolic enzymes an easier 
process in recent years. These advancements allow for the production of novel compounds and 
small-molecule inhibitors with increased specificity and uptake, promoting more personalized 
anti-cancer therapeutic approaches. More than ever, we are equipped with both the knowledge and 
technology to establish more effective therapies for GBM.  
In this study we have added to the framework of past reports demonstrating the high 
plasticity of GBM cells to adapt to changes in nutrient availability and to establish a unique 
 98 
phenotype that drives tumorigenesis. To this end, the work presented here has elucidated several 
important factors that should be taken into account when designing future treatments for GBM. 
Our results with IDH mutant cultures demonstrate that IDH mutant GBMs represent a distinct 
class of glioma with unique characteristics that differentiate them from their IDH wildtype 
counterparts. Our experiments reveal that IDH mutant cells display clear differences in expression 
patterns, glucose utilization, ROS production, nucleotide biosynthesis, and DNA repair capacity 
with the potential to be exploited for therapy. Furthermore, our assessment of fatty acid (FA) and 
ketone metabolism highlight that while glycolysis is a major pathway activated in GBM, 
alternative metabolic substrates may serve equally important physiological roles. We discovered 
extensive utilization of FAs throughout the GBM metabolome under physiological glucose 
conditions, identified CPT1-mediated fatty acid oxidation (FAO) as a potential therapeutic target, 
and determined that dietary intervention should be approached with caution, as our results indicate 
that the ketogenic diet (KD) can have adverse effects on tumor growth. 
 
Informing Therapeutic Strategies for GBM: 
IDH mutations: 
IDH mutations represent attractive therapeutic targets for several reasons. Recent studies 
offer compelling evidence that IDH mutations occur very early in gliomagenesis and are therefore 
present in the majority of gliomas.  IDH1 mutations are found in approximately 80% of low grade 
gliomas45, 46, 47 and are present in GBM, albeit within a smaller percentage of these more aggressive 
tumors48, 49. This would seem to provide a certain degree of homogeneity in an otherwise highly 
heterogenous disease. Our clustering analysis of both expression (KEGG) and metabolic (LC-MS) 
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profiles support this idea by demonstrating that IDH mutant and wildtype gliomaspheres have clear 
and distinguishing characteristics. In particular, our experiments that show increased DNA repair 
capacity following radiation and a greater dependence on the nucleotide salvage pathway in IDH1 
mutants have direct therapeutic application. If, as we propose, endogenous IDH1 mutants have a 
greater capacity for DNA repair following radiation, it brings into question the efficacy of radiation 
therapy for this subset of tumors. We also demonstrated that IDH1 mutant cells maintain elevated 
levels of ROS, a potential buffering adaptation that makes them more resistant to radiation-induced 
production of free radicals. There are a number of cellular pathways activated upon exposure to 
radiation that can disrupt mitochondrial function and lead to both immediate and persistent changes 
to nucleic acid, protein, and lipid metabolism200. IDH1 mutant cell utilization of both the de novo 
and salvage pathways for nucleotide synthesis may thus represent an additional mechanism that 
contributes to resistance. 
Standard of care for GBM, which includes radiation and treatment with the alkylating agent 
temozolomide (TMZ), offers little benefit to long-term patient survival11. Our data suggest that, 
contrary to IDH WT cells which rely primarily on de novo nucleotide synthesis, inhibition of both 
de novo and salvage pathways may be required to overcome resistance to current therapy. The 
development of IDH mutant-specific inhibitors has shown some promise in certain cancers both 
in vitro and in vivo. Enasidenib is currently approved for treatment of IDH2-mutated acute myeloid 
leukemia (AML) and ivosidenib, an IDH1-mutant inhibitor, has entered clinical trials160. The 
literature surrounding whether the IDH phenotype is a result of the IDH mutation itself, the 
resulting 2-HG production, disruption of wildtype IDH function, or a combination the three, has 
yet to be fully established. However, the effects of IDH mutant-specific inhibitors in a clinical 
setting offers a promising new outlook in the field. The results presented here and in Chapter 2 of 
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this dissertation suggest new avenues for implementing combinatorial therapies that directly target 
the unique metabolic phenotype of IDH mutant tumors. 
Fatty Acids and Ketone Bodies: 
 Over the past several decades, the role of glucose metabolism in brain tumors has been 
extensively documented. Oncogenic signaling networks commonly activated in GBM, such as 
PI3K/Akt/mTOR, promote the use of aerobic glycolysis and have led some to propose a state of 
“glucose addiction”. This has led researchers to theorize that metabolic targeting or dietary 
intervention, such as the KD, may serve as effective adjuvant therapies. However, results of 
targeting glucose metabolism have fallen short of expectation. Recent studies, including the one 
presented in Chapter 3, reveal a high plasticity of glioblastoma cells to change metabolic dynamics 
based on nutritional supply. Here we report that while glucose is a necessary component of GBM 
metabolism, utilization of FAs and ketone bodies (KBs) represent two additional substrates that 
require consideration for improving therapy.  
One of the more unexpected findings of this study was the observation that the KD resulted 
in increased U87 tumor growth in our mouse xenotransplant models. Numerous groups have 
investigated dietary manipulation, such as the KD or calorie restriction, with reports ranging from 
no effect to varying levels of success82, 96, 182, 183. One of the potential reasons for the observed 
increase in tumor growth may be due to the length of KD implementation. Our study utilized a 
long-term KD that far exceeds the typical length of previous dietary experimental designs. While 
unexpected, our results investigating ketone metabolism highlight the ability of GBM cells to 
oxidize KBs while also suggesting that future clinical trials investigating such treatments proceed 
with a great deal of caution.  
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The current study also suggests that under physiologically relevant glucose conditions, 
GBMs can oxidize FAs to support bioenergetic demands and cellular maintenance regardless of 
Akt-activating mutations, such as EGFR and PTEN, that have been implicated in glucose 
addiction. Inhibitors of EGFR (such as erlotinib, gefitinib, and lapatinib) have been investigated 
clinically, but none exhibited efficacy either alone or in combination with the other drugs or small 
molecule inhibitors tested37, 38, 39, 40. Early clinical trials with PI3K inhibitors yielded a similar 
result42. One reason for therapy resistance may be due to the ability of GBMs to oxidize FAs. 
Based on our observations with CPT1 inhibition, it is reasonable to hypothesize that combining 
inhibitors of EGFR/PI3K/Akt and of FAO would elicit a more potent response. Simultaneous 
inhibition of oncogene-driven glycolysis (EGFR/PI3K/Akt) and CPT1A-driven FAO would 
preferentially target the tumors’ metabolic adaptability over healthy surrounding tissue, as both 
enzyme expression and activity of these pathways are significantly elevated in GBM. The 
orthotopic xenograft model used in Figures 19 -20 could serve as a useful platform to test this 
theory, as U87 cells are PTEN deficient and thus have inherent Akt activation. Utilizing a primary 
GBM cell line would be the preferred route of investigation for physiologic relevance. As with 
any treatment approach, monitoring the subjects’ health will be paramount. Etomoxir itself may 
not be an ideal compound for CPT1 inhibition as it has shown off-target effects in vitro80 and 
toxicity in vivo201. However, there are other inhibitors of both pathways currently available or in 
development that offer exciting new therapeutic opportunities43, 202. 
Due to the poor prognosis of GBM and the currently insufficient treatment options 
available, the work presented here emphasizes several important characteristics of glioma 
metabolism with the potential for direct therapeutic application. GBM represents a unique, 
complex, and formidable metabolic disease. While the intricacies of oncogenic signaling and 
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metabolic networks make targeting GBM an immense challenge, studies such as this bring us one 
step closer to understanding the underlying mechanisms of pathogenesis and to developing more 
effective precision-guided therapies. 
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